 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 1 of 92 
 
Neurolief Confidential  
  
  
 
Neurolief  
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  The MOOD  study – external Combined Occipi[INVESTIGATOR_132445] (eCOT -NS) for the treatment of 
Major Depressive Disorder (MDD)  
Clinical Investigation Plan Identifier  SP-201-MOOD  
Study Product Name  [CONTACT_132655] ®DP  
Sponsor/ US Agent  Neurolief  Ltd. 
12 Giborei Israel  
Netanya, 4250412  Israel  
Phone: [PHONE_2959]  
Contact: [CONTACT_132527] -Datel   
e-mail: michal.kedar -datel @neurolief.com     
 
US Agent :  
Chris Richardson  
[ADDRESS_149687]  
Tampa, FL   [ZIP_CODE]  
[LOCATION_003] 
Tel: +1 -888-4Relivion/888 -473-5484  
 
Document Version  Rev. 3 / [ADDRESS_149688]  know  that it is confidential  and that it 
may  not be further  disclosed  by [CONTACT_476].  
 
 
 
  
Doc No.: CL-CIP-201 
MOOD: ONeurolief Rev: REV.3/09June2021 Brain Innovation CLINICAL INVESTIGATION PLAN 
Pg. 2 of 92 
Approvals 
Prepared by: 
[CONTACT_132528]- Date 
Approved by: 
[CONTACT_132529] 2- 2 2 
Position Michal Kedar-Datel Date 
Biostatistician 
BioStatsStatistical Consulting Ltd. 
Position Lisa Deutsch, PhD Date 
Neurolief Confidential 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149689] Name  [CONTACT_132655] ®DP 
Sponsor  Neurolief  Ltd. 
Clinical Investigation Plan Identifier  SP-201-MOOD  
Version Number/Date  Rev. 3 / [ADDRESS_149690] of the clinical investigation without the prior written consent of 
Neurolief . 
 
I will provide all study personnel under my supervision cop ies of the protocol and access to all 
information provided by [CONTACT_132530] . I will discuss this material with them to ensure that they are fully 
informed about the products and the study.  
 
Investigator’s Signature:   
 
 
[CONTACT_10670]’s Name:   
 
[CONTACT_16277]:   
 
Date:    
 
 
  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149691] Description  ................................ ................................ ................................ ....... 25 
6.1. Gener al ................................ ................................ ................................ ................................ . 25 
6.2. Proposed Mode of Action  ................................ ................................ ................................ ........  26 
6.3. Dosage Form  ................................ ................................ ................................ .........................  27 
6.3.1.  Double Blind Phase  ................................ ................................ ................................ ...............  27 
6.3.2.  Open Label Phase  ................................ ................................ ................................ ..................  27 
6.4. Manuf acturer & Device Version  ................................ ................................ ...............................  28 
6.5. Packaging & Supply ................................ ................................ ................................ ................  28 
6.5.1.  Source ................................ ................................ ................................ ................................ .... 28 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 5 of 92 
 
Neurolief Confidential  
  
  
6.5.2.  Labeling  ................................ ................................ ................................ ................................ . 28 
6.5.3.  Storage  ................................ ................................ ................................ ................................ .. 29 
6.6. Intended Use & Intended Population  ................................ ................................ .......................  [ADDRESS_149692]  Enrollment  ................................ ................................ ................................ .................  41 
8.3. Inclusion Criteria  ................................ ................................ ................................ ....................  42 
8.4. Exclusion Criteria  ................................ ................................ ................................ ...................  43 
8.5. Vulne rable Population ................................ ................................ ................................ .............  44 
9. Study Procedures ................................ ................................ ................................ ...........  45 
9.1. Schedule of Events  ................................ ................................ ................................ .................  45 
9.1.1.  Visit 1 – Screening (Day -14- 0) Screening and Preliminary Eligibility Assessment.  ..............  46 
9.1.2.  Visit 2 – Baseline (Day -4 - 0) Eligibi lity evaluation, Randomization and device training.  .... 46 
9.1.3. Daily treatment period (Day 0 - day 56±7)  ................................ ................................ ............  47 
9.1.4.  Visit 3 – 4 weeks Follow up (Day 28±7)  ................................ ................................ .................  47 
9.1.5.  Visit 4 – end of the DB phase (Day 56±7)  ................................ ................................ ..............  48 
9.1.6.  Open label extension phase (Day 56±7 - day 112±7)  ................................ .............................  49 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 6 of 92 
 
Neurolief Confidential  
  
  
9.1.7.  Visit 5 – 12 weeks Follow up (Day 84± 7) ................................ ................................ ...............  50 
9.1.8.  Visit 6 – end of study (Day 112±7)  ................................ ................................ ........................  51 
9.2. Activities Performed by [CONTACT_2728]’s Personnel  ................................ ................................ ............  [ADDRESS_149693] / Visit  ................................ ................................ ...........................  58 
10. Risks and Benefits  ................................ ................................ ................................ .........  59 
10.1.  Potential Risks  ................................ ................................ ................................ ..................  59 
10.2.  Potent ial Benefits  ................................ ................................ ................................ .............  60 
10.3.  Risk Control and Mitigation  ................................ ................................ ...............................  60 
10.4.  Risk-Benefit Rationale  ................................ ................................ ................................ ....... 60 
11. Adverse Events and Device Deficiencies  ................................ ................................ ....... 60 
11.1.  Definitions  ................................ ................................ ................................ .......................  61 
11.2.  Relivion®DP Anticipated Adverse Events  ................................ ................................ ..............  62 
11.3.  Reporting of Adverse Events  ................................ ................................ .............................  63 
11.3.1.  Reportable Adverse Events  ................................ ................................ ...............................  63 
11.3.2.  Hospi[INVESTIGATOR_602]  ................................ ................................ ................................ .................  63 
11.3.3.  Reporting Procedures  ................................ ................................ ................................ ........  63 
11.3.4.  Reporting of Adverse Events  ................................ ................................ .............................  66 
11.3.5.  Notification to Authorities  ................................ ................................ ................................ . 67 
11.3.6.  Device Deficiencies  ................................ ................................ ................................ ............  67 
11.3.7 . Safety Monitoring and Adjudication of Adverse Events  ................................ ....................  68 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 7 of 92 
 
Neurolief Confidential  
  
  
12. Statistical Considerations  ................................ ................................ ..............................  69 
12.1.  Study Design and Objectives  ................................ ................................ .............................  69 
12.1.1.  Objectives  ................................ ................................ ................................ ..........................  69 
12.1.2.  Study Design  ................................ ................................ ................................ ......................  69 
12.2.  Study  Endpoint Variables  ................................ ................................ ................................ .. 69 
12.2.1.  Primary endpoint variable  ................................ ................................ ................................ . 69 
12.2.2.  Secondary and exploratory endpoint variables  ................................ ................................ . 69 
12.2.3.  Safety endpoint variables  ................................ ................................ ................................ .. 70 
12.3.  Study Hypothesis  ................................ ................................ ................................ .............  70 
12.4.  Sample Size Estimation  ................................ ................................ ................................ ..... 70 
12.5. Interim Analysis  ................................ ................................ ................................ ...............  71 
12.5.1.  Procedure  ................................ ................................ ................................ ..........................  71 
12.5.2.  Blinding  ................................ ................................ ................................ ..............................  72 
12.5.3.  Decision  Rules  ................................ ................................ ................................ ....................  72 
12.5.4.  Controlling the Alpha Level for the Primary Endpoint  ................................ ......................  73 
12.6.  Randomization  ................................ ................................ ................................ .................  73 
12.7.  Study Analysis Populations  ................................ ................................ ................................  73 
12.7.1.  Intent -to-Treat (ITT) Population:  ................................ ................................ .......................  73 
12.7.2.  Modified Intent -to-Treat (mITT) Population:  ................................ ................................ .... 74 
12.7.3.  Per-Protocol Population:  ................................ ................................ ................................ ... 74 
12.7.4.  Modified Younger Intent -to-Treat (mYITT) Population:  ................................ ....................  74 
12.7.5.  Statistical Analysis of Analysis Sets  ................................ ................................ ....................  74 
12.8.  Statistical Analysis  ................................ ................................ ................................ ............  74 
12.8.1.  General Considerations  ................................ ................................ ................................ ..... 74 
12.8.2.  Significance Level and Handling of Type I Error  ................................ ................................  75 
12.8.3.  Demographic and Other Baseline Characteristics  ................................ .............................  75 
12.8.4.  Disposition of Subjects  ................................ ................................ ................................ ...... 76 
12.9.  Efficacy Analysis  ................................ ................................ ................................ ...............  76 
12.9.1.  Primary Efficacy Analyses  ................................ ................................ ................................ . 76 
12.9.2.  Secondary Efficacy Analyses  ................................ ................................ ..............................  77 
12.9.3.  Exploratory Analyses  ................................ ................................ ................................ .........  78 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 8 of 92 
 
Neurolief Confidential  
  
  
12.9.4.  Safety Analysis  ................................ ................................ ................................ ...................  78 
12.9.5.  Handling of Missing Data  ................................ ................................ ................................ ... 78 
12.9.6.  Pooling  ................................ ................................ ................................ ...............................  79 
13. Ethics  ................................ ................................ ................................ .............................  79 
13.1.  Statement(s) of Compliance  ................................ ................................ ..............................  [ADDRESS_149694] Access to Source Data/Documents  ................................ ................................ ...........  [ADDRESS_149695] Retention  ................................ ................................ ................................ .............  85 
14.10.  Publication and Use of Information  ................................ ................................ ....................  85 
14.11.  Funding  ................................ ................................ ................................ ...........................  86 
14.12.  Suspension or Early Termination  ................................ ................................ .......................  86 
15. References  ................................ ................................ ................................ .....................  87 
16. Version History  ................................ ................................ ................................ ..............  91 
17. Appendixes  ................................ ................................ ................................ ....................  92 
  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149696]  
AE Adverse Event  
ADHD  Attention Deficit Hyperactivity Disorder  
ATRF Antidepressant  Treatment Resistance Form  
ATIF Antidepressant  Treatment Intolerance  Form  
C-SSRS  Columbia – Suicide Severity  Rating  Scale  
CAPA  Corrective and Preventive Action  
CFR Code of Federal Regulation  
CGI-S Clinical Global Impression scales - Severity  
CGI-I Clinical Global Impression scales – Improvement  
CIP Clinical Investigation Plan  
CP Conditional Power  
CRF Case Report Form  
EC Ethics Committee  
DBS  Deep Brain Stimulation  
DSM -V Diagnostic and Statistical Manual of Mental Disorders - V 
eCRF  Electronic Case Report Form  
eCOT -NS external Combined Occipi[INVESTIGATOR_132446] /MADRS  Montgomery -Asberg Depression Rating Score  
mITT  modified Intent to Treat  
MOH  Ministry of Health  
NSR Non -Significant Risk  
OCD  Obsessive  Compulsive Disorder   
ONS  Occipi[INVESTIGATOR_132447]  
P/N Part Number  
PNS Peripheral Nerve Stimulation  
PTSD  Post -Traumatic Stress  
QIDS  Quick Inventory of Depressive Symptomatology  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149697]  
SAE Serious Adverse Event  
SCID  Structured Clinical Interview for DSM -V 
TENS  Transcutaneous Electrical Nerve Stimulation  
TMS  Transcranial Magnetic Stimulation  
TNS Trigeminal Nerve Stimulation  
UM User Manual  
US [LOCATION_002]  
U(S)ADE  Unanticipated (Serious) Adverse Device Effect  
VAS Visual Analogue Scale  
 
 
  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 11 of 92 
 
Neurolief Confidential  
  
  
3. Synopsis  
Title  The MOOD study - Safety and efficacy of external Combined Occipi[INVESTIGATOR_132448] ( eCOT -NS) for the treatment of Major Depressive Disorder (MDD)  
Clinical Study 
Type  Pi[INVESTIGATOR_22735], Pre -market, Non -Significant Risk (NSR) Device Study  
Product Name  [CONTACT_132655]® DP (Device version PLV3; SW version [IP_ADDRESS]; App Version  1.2) 
Sponsor  Neurolief Ltd.  
Indication 
under 
investigation  The Relivion® DP external Combined Occipi[INVESTIGATOR_132449] (eCOT -NS) is 
intended as an adjunctive treatment to pharmaceutical management of Major Depressive 
Disorder (MDD) in adults  who failed to achieve satisfactory improvement from previous 
Antidepressant  medication treatment . The Relivion® DP is a prescription device  for patient at 
home, self -use. 
Investigation 
Purpose  The MOOD Study will evaluate the safety and efficacy   of a self -administered treatment for 
MDD using an external combined occipi[INVESTIGATOR_132450] ( Relivion® DP). 
This pi[INVESTIGATOR_132451] i nvestigation is intended to support future marketing  
applications (US FDA and CE) for Neurolief’s Relivion ®DP device . 
 
Product Status  Pre-market  
Patient 
Population  Male and female; 18 – 70 years of age; Primary diagnosis by [CONTACT_9288] -V criteria for MDD  
Primary 
Objectives  To assess the change in  depressive symptoms, from baseline to [ADDRESS_149698] treatment 
initiation when using active external combined occipi[INVESTIGATOR_132452] 
(Relivion® DP), compared to sham stimulation ( Relivion® DP-Sham), in subjects suffering from 
MDD. Depressive symptoms severity will be assessed by [CONTACT_132531] 17 depression scale total 
score.  
Secondary 
Objectives  
 • To assess the proportion of subjects achieving  at least 50% improvement 
(“responders”) in the HDRS [ADDRESS_149699] treatment 
initiation when using the Relivion® DP device  compared to sham stimulation 
(Relivion® DP-Sham), in subjects suffering from MDD.  
• To assess the proportion of s ubjects achieving remission (HDRS 17 score ≤7) at the [ADDRESS_149700] treatment initiation when using the Relivion® DP device  compared to sham 
stimulation ( Relivion® DP- Sham), in subjects suffering from MDD.  
• To assess the change in  depressive symptoms, from baseline to [ADDRESS_149701] 
treatment initiation when using the Relivion® DP device  compared to sham stimulation 
(Relivion® DP-Sham), in subjects suffering from MDD. Depressive symptoms severity 
will be assessed by [CONTACT_132532].  
 
 
Safety 
Objective  To demonstrate the safety of the Relivion® DP device in subjects suffering from Major 
Depressive Disorder (MDD).  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 12 of 92 
 
Neurolief Confidential  
  
  
Exploratory 
Objectives  • To assess the change on the Clinical Global Impression (CGI)  scale for Improvement 
(CGI -I) and change on the CGI -Severity scale (CGI -S) from baseline to [ADDRESS_149702] 
treatment initiation when using the Relivion® DP device compared to sham stimulation 
(Relivion® DP-sham), in subjects suffering from MDD.  
• To assess the changes in total score on the 16 -Item Quick Inventory of Depressive 
Symptomatology Self -Rated (QIDS -SR-16) score  from baseline to [ADDRESS_149703] 
treatment initiation when using the Relivion® DP device compared to sham stimulation 
(Relivion® DP-Sham), in su bjects suffering from MDD.   
• To assess the change in depressive symptoms from baseline to [ADDRESS_149704] treatment initiation when using the Relivion® DP device  
compared to sham stimulation (Relivion® DP-Sham) in subjects  
suffering from MDD. Depressive symptom s severity will be  
assessed by [CONTACT_132531] [ADDRESS_149705] will participate in the study for up to 20 weeks  (including the screening 
period) . 
The duration of the treatment protocol for each subject will be 8±1 weeks of a double blind  
active or sham treatment  phase , followed by 8±[ADDRESS_149706] approximately 18 months.   
Study Design  This is a prospective, multi -center, 2 -arm randomized, parallel group, double -blind sham -
controlled study  followed by [CONTACT_132533] . 
 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 13 of 92 
 
Neurolief Confidential  
  
  
 
Study design Flowchart  
 
 

 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 14 of 92 
 
Neurolief Confidential  
  
  
The study will include the following study visits & phases : 
• Visit 1 - Screening (Day ( -14)-0) - Screening & Preliminary Eligibility Assessment.  
• Visit 2 - Baseline (Day (-4)-0) – Eligibility, baseline assessment , Randomization to 
Relivion® DP vs. Sham control (1:1 randomization)  and training . 
• Double blind phase  (Day 0 to day 56±7)- 5-7 days a week  treatment: Active/ Sham 
treatment  protocol.  
• Visit 3 - Follow Up Visit (day 2 8±7)- MDD assessment.  
• Visit 4 - End of Double -Blind phase (day 56±7)- MDD assessment . 
• Open label phase – Active treatment period:  According to HDRS response in DB 
phase, in between Maintenance  treatment 3-4 times a week and up to 5-7 days a 
week of intensified  treatment (Day 56±7 to day 112±7) 
• Visit 5 - follow up visit (day 84±7) - MDD assessment . 
• Visit 6 - End of study (day 112±7)- MDD assessment and end of study . 
After completion of the open label period the subject’s participation in the study will be 
over.  
Randomization  Eligible subjects will be randomly allocated (with a 1:1 ratio) to one of the following 2 
treatment groups based on a randomization scheme using the permuted block method 
stratified by [CONTACT_384]:  
• Active stimulation  
• Sham stimulation  
The randomization scheme will be prepared by [CONTACT_132534] (version 
9.4.) random number procedure. The block size will be random, and all study personnel will 
be therefore blinded to the randomization block size.  
Sample Size  The overall calculated sample size is up to 124  randomized subjects aged 22 -70 to allow for 
53 evaluable subjects per treatment group, anticipating a 15% drop -out, plus an additional 
up to 36 randomized subjects aged 18 -21 to allow 15  evaluable subjects per treatment group.  
The study will follow a sample size adaptive design with one interim analysis planned to allow 
for sample size increase , completion per original sample size , stop for futility  or stop for 
efficacy . One interim analysis is plan ned after 86 (~80% of the calculated adult sample size ) 
evaluable subjects have been accrued.   
Inclusion 
Criteria  1. Males and females 18 -70 years of age : 
a. Up to 124 randomized subjects aged 22 -70 
b. Up to 36 randomized subjects aged 18 -21 
2. Primary diagnosis of unipolar major depressive disorder by [CONTACT_2681] -V criteria.  
3. Current MDD epi[INVESTIGATOR_132453].  
4. Score on the Hamilton Depression Rating Scale (HDRS 21) > 20 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 15 of 92 
 
Neurolief Confidential  
  
  
5. Symptoms of current major depressive epi[INVESTIGATOR_132454], as determined by [CONTACT_737] , 
for the current epi[INVESTIGATOR_132455] 
(ATRF) or Antidepressant Treatment Intolerance  Form (ATIF):  
• Did not respond or have insufficiently responded by [CONTACT_21316] 50% improvement; 
dose and duration defined & r ated at minimum confidence level 3 on the ATRF;  
• Did not respond or has insufficiently responded to at least one but no more than four 
adequate trials of antidepressant medications (4 ≥ ATRF ≥1) or  
• Did not respond or has insufficiently responded due to poor tolerability to at least 
two inadequate antidepressant medication trials (ATIF ≥2).  
6. Subject must be on at least one (1) antidepressant medication (minimum therapeutic 
dose not required if tolerability precluded further dose titration) and is willing t o remain 
on the same daily dose of antidepressant medication(s) for a minimum of [ADDRESS_149707] s receiving current depression focused psychotherapy: psychotherapy 
initiated at least  [ADDRESS_149708] has cognitive and/or motor skills needed to operate a smartphone and can be 
contact[CONTACT_3012] , as determined by [CONTACT_737] . 
 
Exclusion 
Criteria  1. History of intracranial surgery .  
2. Current denervation in one or more of the follow ing: the supraorbital or supratrochlear 
branches of the trigeminal nerve, or the greater occipi[INVESTIGATOR_132456] . 
3. An implanted neurostimulators or any implanted metallic or electronic device in the 
head, a cardiac pacemaker or an impl anted or wearable defibrillator, except for dental 
implants.  
4. Skin lesion , scars,  or inflammation at the region of the stimulating electrodes.  
5. Subject s with a history of traumatic brain injury (TBI), defined as a disruption in the 
normal function of the bra in that can be caused by a bump, blow, or jolt to the head, or 
penetrating head injury, within 3 months of study enrollment.  
6. Pregnancy or Lactation.  
7. Women  of reproductive age not using a reliable contraceptive  method  as determined by 
[CONTACT_737].  
8. In the opi[INVESTIGATOR_689], subjects with a psychiatric history consistent with, 
suspi[INVESTIGATOR_271], or diagnostic of, bipolar depression or depression associated with 
psychosis.  
9. Borderline personality disorder, defined by [CONTACT_2681] -V criteria, that in the judgement of the 
Investigator is likely to complicate the assessment of clinical response to study 
treatments or limits the patient’s ability to comply with study procedures . 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 16 of 92 
 
Neurolief Confidential  
  
  
10. Subjects who, within one (1) year of study enrollment, have a history consistent with, 
suspi[INVESTIGATOR_132457], any of the following: psychosis, psychotic disorder, 
schizophrenia or schizoaffective disorder, in the opi[INVESTIGATOR_689].  
11. Subjects who demonstrate or have a history of any cognitive disorder or impairment, 
memory loss, dementia, confusion or delirium that, in the opi[INVESTIGATOR_689], 
may compromise the integrity of the study data or impact the ability of the subject to 
comply with the study requirements.  
12. Past 12 months active suicidal intent or plan as defined by a “yes” answer to Q4 or Q5 on 
the Columbia -Suicide Severity Rating Scale, (C -SSRS) or  with a history of suicide attempt 
in the past twelve months.  
13. Subjects currently (past month) meeting diagnostic criteria for Obsessive -Compulsive 
Disorder or post -traumatic stress disorder and that is their primary diagnosis . 
14. Subjects meeting the DSM -V criteria for alcohol use disorder or other substance use 
disorder (not including tobacco/nicotine) within six (6) months prior to study enrollment.  
15. The s ubject has any past or present medical condition, disease, illness, disorder or injury 
that, in the opi[INVESTIGATOR_689], may reduce or hinder the subject’s ability to fully 
comply with all study requirements for the duration of the study or may con found the 
integrity of the study data.  
16. Participation in a previous study with the Relivion® DP  or the Relivion ® device.  
17. Treatment with Transcranial Magnetic Stimulation (TMS)  in the past 6 months.  
18. Current treatment with any other approved or investigation al brain stimulation 
therapi[INVESTIGATOR_014] (i.e. Vagus or trigeminal nerve Stimulation, tDCS, TES) . 
19. Failure to receive clinical benefit from an adequate trial of ECT in the current or a past 
depressive epi[INVESTIGATOR_132458] . 
20.  Subject having received Botox treatment in the head or neck region within [ADDRESS_149709] treatment initiation . 
 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 17 of 92 
 
Neurolief Confidential  
  
  
Secondary 
Efficacy 
Endpoints  • Proportion of responder subjects - defined as the percent of subjects achieving at 
least 50% reduction from baseline in their HDRS [ADDRESS_149710] 
Relivion® DP treatment initiation.  
• Proportion of subjects achieving remission - defined as the percent of subjects with 
HDRS 17 score ≤[ADDRESS_149711] Relivion® DP treatment initiation.  
• Mean change in depressive symptoms, measured by [CONTACT_132535], from 
baseline to week -[ADDRESS_149712] treatment initiation.  
Safety 
Endpoint  Safety of the study device following study treatment: Incidence of adverse events and 
serious adverse events related or unrelated to the study device [Time Frame: up to [ADDRESS_149713] treatment initiation].  
Exploratory 
Endpoints  • Mean Change in the severity  and improvement scores - Clinical Global Impression scales 
(CGI -S and CGI -I) at [ADDRESS_149714] treatment initiation.  
• Mean Change from baseline in total score of the Quick Inventory of Depressive 
Symptomatology self -rated (QIDS -SR-16) score  at [ADDRESS_149715] t reatment initiation.  
• Mean change in depressive symptoms, measured by [CONTACT_132536] [ADDRESS_149716] Relivion® DP treatment initiation . 
 
 Statistical 
Considerations  Study Hypothesis :  
Null hypothesis: Mean change from baseline in HDRS [ADDRESS_149717] treatment initiation 
in subjects suffering from Major Depressive Disorder (MDD) in the active Relivion® DP arm = 
Mean change from baseline in HDRS [ADDRESS_149718] treatment initiation in the sham arm.   
Alternative hypothesis: Mean  change  from baseline in HDRS [ADDRESS_149719] treatment 
initiation in subjects suffering from Major Depressive Disorder (MDD) in the active 
Relivion®DP  arm ≠ Mean change from baseline in HDRS [ADDRESS_149720] treatment initiation 
in the sham arm.   
Statistical  Analysis : 
Study Analysis Sets  
Each of the following analysis sets will be evaluated for the principal statistical analysis:  
Intent -to-treat Analysis Set (ITT)  
The intent -to-treat (ITT) population will include all subjects enrolled in the study , aged [ADDRESS_149721] one 
active/sham treatment. According to the ITT principle all subjects will be analyzed in the 
treatment group as assigned by [CONTACT_17628].  
Modified Intent -to-treat Analysis Se t (mITT)  
The modified intent -to-treat (mITT) population will include all subjects from the ITT set 
enrolled in the study, who completed the minimal stimulation time required by [CONTACT_132537]. The mITT analys is set will be analyzed in 
the treatment group as treated.  
Per-Protocol Analysis set (PP)  
All subjects from mITT set that complete the 8-week treatment period (without withdrawal) 
and without any major protocol deviations.  
Modified Younger Intent -to-Treat (mYITT) Analysis Set  
The modified younger intent -to-treat (mYITT) population will include all subjects from the ITT 
set enrolled in the study including subjects aged 18 -21, who completed the minimal 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149722] randomization exclusion criteria. 
The m YITT analysis set will be analyzed in the treatment group as treated.  
Statistical Analysis of Cohorts Analysis Sets  
Safety assessments will be performed on the ITT  and mYITT  analysis set s. 
The mITT cohort will serv e as the principal data analysis set for the primary and secondary 
statistical efficacy endpoints.  The primary, secondary and exploratory efficacy assessment 
will also be performed on the per protocol (PP) analysis set for descriptive purposes and to 
show  consistency of study results.  Primary and secondary efficacy analysis will be performed 
on the mYITT set as well.  
Interim Analysis  
An interim analysis will be performed by [CONTACT_132538] 80% of the 
required number of subjects  aged 22-[ADDRESS_149723] treatment initiation visit.  
Depending on the outcome of the interim analysis, the study will either continue to the 
originally planned sample size, stop for futility, stop for efficacy, or continue w ith an 
increased sample size. These decisions will be made based on the conditional power (CP), 
which is defined as the conditional probability that the result will exceed a critical value at 
the interim given the observed effect size.  
Note that the interi m analysis will be conducted on all populations (ITT, mITT , PP and mYITT 
analysis sets), and the study will be stopped due to futility only if the interim effects in all 
populations fall below the threshold .  
 
Handling of the Type I Error  
The overall significance level for this study is 5% using two -tailed tests, except for treatment 
by [CONTACT_132539] a significance level of 10%.  
 
Controlling the Overall Type I Error:  
The hierarchy approach will be adopted for the primary and secondary endpoints to control 
type I error due to multiple endpoint testing. It is rec ognized that the ordering is important 
only with regard to rejection or non -rejection of the null hypothesis. Thus, the first endpoint 
will first be analyzed  and only if p≤0.05, will the second endpoint be analyzed, and so on.  
General  
Data will be analyzed using SAS ® version 9.4 or higher (SAS Institute, Cary North Carolina). 
All statistical tests will be two -sided.  
Study data will be summarized with descriptive statistics and presented in tables and figures. 
Continuous variables will  be summarized by a mean, standard deviation, minimum, median 
and maximum and categorical variables by a count and percentage. For comparison of means 
(continuous variables), the two -sample t -test or the Wilcoxon rank sum test will be used as 
appropriate. For comparison of proportions (categorical variables), the chi -squared test or 
Fisher’s exact test will be used as appropriate. If multiple measurements are taken in a single 
subject, statistics described below will be appropriately modified to accommodate  the within 
subject correlation.  
Primary Endpoint Analysis  
The primary efficacy endpoint is the change from baseline to [ADDRESS_149724] treatment 
initiation in HDRS 17 score.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149725] treatment initiation will be compared 
between the treatment groups using a repeated measures analysis of covariance (ANCOVA, 
SAS® MIXED procedure). The model will include the following fixed effects: treatment group, 
visit, treatment group by [CONTACT_132540] 17 and center entered  as 
covariates. Baseline HDRS 17 scores will be entered as a continuous variable so that the 
potential for co -linearity problems will be minimized. The treatment group by [CONTACT_132541] l, but not as part of the principal statistical evaluation. Additionally, the 
center variable will be grouped by [CONTACT_132542] (OUS) and the analyses for 
center will repeated on this new variable.  
Safety analysis  
The primary safety variabl e, the cumulative incidence (and 95% CI) of device related adverse 
events (AEs) throughout the study, will be presented in tabular format and will include 
incidence tables by [CONTACT_926].  
Adverse event rates will be compared between the study groups with a F isher’s exact test.  
 
 
 
4. Introduction  
Background  
Major Depressive Disorder (MDD)  
Major Depressive Disorder (MDD) is a common, disabling  and undertreated condition associated with 
significant morbidity. MDD  affects approximately  350 million people of all ages  globally . It was classified 
by [CONTACT_38375] (WHO) as the 4th  leading cause of disability worldwide and it has been 
estimated that by 2020, it would be the second leading cause [1]. During 2020 , with the  global outbreak 
of the COVID -19 virus, depression prevalence has undergone a major  increase  in the US  and globally  [2]. 
In fact, Bueno -Notivol et al . (2020) report that c ompared with a global estimated prevalence of depression 
of 3.44% in 2017, they found a  7 times higher pooled prevalence  of 25% , thus suggesting the immergence 
of a global mental health crisis [2]. 
MDD  is a clinical condition characterized by [CONTACT_132543][INVESTIGATOR_132459]. These epi[INVESTIGATOR_132460], anhedonia (lack of pleasure in p reviously 
pleasurable activities) and accessory symptoms like alterations in sleep, appetite, psychomotricity, 
pessimistic thoughts, and even attempts of suicide. Half of the epi[INVESTIGATOR_132461], and in one -third of 
them, treatment refractoriness occurs  (symptoms persist despi[INVESTIGATOR_132462]) [3].  
If depression is not treated, i t can become chronic (long -lasting). Treatment can shorten the length and 
severity of a depressive epi[INVESTIGATOR_1865]  [4], [5] . Currently, the most common treatments for MDD are 
medication s, psychotherapy, attending support groups or a combination of these treatments.   It has been 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 20 of 92 
 
Neurolief Confidential  
  
  
reported that patients show an improvement in their depression symptoms generally within four to six 
weeks from the beginning of treatment  [6]. However, it has been estimated that around 40% of patients 
do not respond adequa tely to the common treatments, including pharmacotherapy and psychotherapy 
[7]. The lack of adherence to medication, the pr esence of adverse effects (e.g. weight gain, sexual 
dysfunction,  insomnia, dizziness, nausea, constipation) and high refractoriness rates altogether generate  
an ultimate need  for alternative non-drug antidepressive therapi[INVESTIGATOR_014], such as neuro stimulation 
technologies  [3]. With demand  for therapeutic solutions which can be self -administere d at home and 
remotely controlled by [CONTACT_132544] -care providers due to the Covid -[ADDRESS_149726] been used in clinical neurology and 
psychiatry, such as electroconvulsive therapy (ECT), repetitive transcranial magne tic stimulation (rTMS), 
vagus nerve stimulation (VNS), transcranial direc t current stimulation (tDCS), deep brain stimulation (DBS)  
and stereotactic surgery and trigeminal nerve stimulation (TNS). Theoretically, such techniques present 
different mechanisms  of action. For instance, ECT nonspecifically increases brain activity and excitability 
through controlled, electrically induced seizures; rTMS through an electromagnetic field induces 
intracortical electric currents which may modulate neuronal activity fo cally; and tDCS modifies brain 
excitability through weak, direct electric currents.  
Out of these methods, peripheral nerve stimulation  (PNS)  has gained much interest , as it presents both 
high therapeutic value , on one hand , and promising  progress in becoming non -invasive on the other. 
Indeed, t he use of PNS for psychiatric and neurological indications has been studied  extensively.  Evidence  
has been reported  for successful  treatment  of symptoms of MDD  as well as  Parkinson’s disease, 
Neuro pathic  pain, Stroke rehabilitation, Smoking Cessation, OCD, PTSD , ADHD  and other pending 
indications  [8]. Several technologies have been approved  by [CONTACT_132545]. MDD   is one of the  most recurrent  indications , consistently 
show ing great therapeutic potential  [8]. 
Neurolief’s Treatment - An External Combined Occipi[INVESTIGATOR_132463] (eCOT -NS)  
Relivion ®DP, an external Combined Occipi[INVESTIGATOR_132463] (eCOT -NS) is proposed as a 
novel treatment for MDD.  The combination of neuromodulation o f both the occipi[INVESTIGATOR_132464]-invasively is made possible  for the first tim e, after having been successfully 
performed  either separately or  in invasive procedures.   
A. Trigeminal Nerve Stimulation (TNS)  
Trigeminal Nerve Stimulation (TNS) is a  noninvasive technology , reported to be well -tolerated, with no 
severe adverse effect and with impressive results for MDD  treatment [8].  Despi[INVESTIGATOR_132465] :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149727] for conveying information to the central nervous system  [8]. It has three major 
sensory branches over the face, all of which are bilateral. The trigeminal ganglion, located in the Meckel 
cave ( ‘cavum trigeminale ’), projec ts to the trigeminal nucleus which makes reciprocal projections to the 
nucleus tractus solitarius ( NTS), locus coeruleus (LC), and reticular formation [9]. Neuroimaging studies of 
TNS show associated neuronal activity changes in certain sites of the brain, such as the amygdala, insula, 
precentral gyrus, hippocampus, and thalamus . It is hypothesized that by a mechanism operating on a 
’bottom -up’ principle , the stimuli propagate from the cranial nerves in the direction of the brainstem and 
central brain areas  [8].   
   
The stimulation of the trigem inal nerve was at first described for treatment -resistant epi[INVESTIGATOR_132466] 
a randomized controlled trial  (DeGiorgio et al. , 2013) [10]. The TNS was performed at home, in an eight -
hour session, during sleep and for eight weeks, with  clinical  improvements observed for the refractory 
epi[INVESTIGATOR_002]. Following the studies on epi[INVESTIGATOR_002], Schrader et al ( 2011 )[11] demonstrated  findings on drug -
resistant  recurrent MDD and PTSD patients , first from a pi[INVESTIGATOR_132467] -label trial with 12 patients . In the later study, patients  underwent TNS by a nocturnal protocol for 
55 sessions during eight weeks , yielding impressive pos itive results (response rates of 75% and 54.5% in 
the HDRS -17, respectively). Following these studies, Shiozawa et al  (2014, 2015) [9], [12]  investigated the 
use of TNS for MDD with changes to the stimulation protocol. The TNS was performed for ten sessions 
during  two weeks. The on/off cycle used in the previous studies was changed to a continuous stimulation 
for [ADDRESS_149728] of the reduced session of TNS , and the authors reported promising results, with a mean reduction 
of 5.72 points in the Hamilton  depression rating scale  (HDRS -17), and with all patients presenting a 
reduction of at least 50% of the depressive symptoms , and ten patients (90.9%) presenting remission of 
depressive symptoms as defined by [CONTACT_132546] -17 [9]. In sequence, the same group 
conducted a randomized, sham -controlled double -blinded study with [ADDRESS_149729] was found to be sustained in a one month follow up evaluation [12]. 
Trevizol et al. (2016 )[13] later evaluated the safety and efficacy for elderly  patients  in an open -label trial 
with ten patients (mean age 73 years), reproducing the results observed in previous studies , with 80% 
response rate and 40% of remission rate by [CONTACT_132531] -17. T he TNS was well tolerated with no severe 
adverse effects reported even for this population  [13]. Due to common pathways involved in anxiety 
symptoms, depressive symptoms and trauma -related disorders, Cook et al.  (2016)  and Trevizol et al.  
(2016)  performed studies on TNS for comorbid MDD and Post -traumatic Stress Disorder (PTSD) with 
twelve and five patients, respectively  [13], [14] . Both groups reported their positive findings on 
depr ession , anxiety and the core symptoms of PTSD, expanding  the possibilities of uses in 
neuropsychiatric disorders.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 22 of 92 
 
Neurolief Confidential  
  
  
 
B. Occipi[INVESTIGATOR_132468]. Stimulation of the occipi[INVESTIGATOR_132469]’s response to 
environmental threats and stress  [15]. It may also indirectly aff ect the mesolimbic dopaminergic system 
and thereby [CONTACT_132547] [16]. The occipi[INVESTIGATOR_132470] -
cervical complex (TCC) from which both nerves have mutual afferent projections to higher cerebra l 
regions such as the insular cortex and the anterior cingulate cortex (ACC) [17]. Invasive neurostimulation 
of the occipi[INVESTIGATOR_132471] [18], [19]  and was also shown 
effective for mood enhancement  [20].  
Due to the challenge of transferring current through the hair, stimulation of the occipi[INVESTIGATOR_132472] [18], [19], [21], [ 22] and percutaneous  [23] nerve stimulators. However, due 
to its superficial anatomic location at the level of the external occipi[INVESTIGATOR_132473] [24], [25] . once the 
electrodes are placed under the hair and close enough to the scalp, it can be stimulated transcutaneously  
[23], thereby [CONTACT_132548].   
C. Combined  Non -Invasive  Trigeminal and Occipi[INVESTIGATOR_132474] (COT -NS) has initially evolved as a treatment for 
migraine . This multi -focal stimulation was termed by [CONTACT_132549] (2015) ‘c oncordant 
paresthesia’   following pi[INVESTIGATOR_132475] s initiated in 2009 [26], and suggested a 
clinically promising approach for pain modulation [27]. Similar evidence for successful eradication of 
headache following invasive concurrent tri gemino -occipi[INVESTIGATOR_132476] [26]–[33]. These reports , when taken together , suggest the possible superiority of multi -focal 
PNS over uni -focal PNS.  However, high co mplication rates  appear across these reports, which highlight 
the obstacle in making this potent, yet invasive, stimulation technology widely accessible , and further 
emphasize the need for a similar non -invasive approach.  
The underlying neural mechanism by [CONTACT_132550]-NS alleviates migraine pain  directly implies  that this 
therapeutic impact may be extended to M DD as well.  The proposed  mechanism of action, detailed in 
section 6.2 (‘proposed mode of action’), points towards a neuro -chemical cascade which  involves  neural 
pathways  associated with  depressio n.  Indeed, results obtained in a prospective, single group, feasibility 
clinical trial which assessed the safety and efficacy of the Relivion ®DP in 23 MDD patients , confirm s eCOT -
NS efficacy for the treatment of depression. High rates of treatment efficacy , as measure d on the HDRS -
17, were found in the sample g roup following treatment. Additionally, anxiety reduction was found as 
well. No serious adverse events were observed. The study and results are further described in section 
7.6.2 (‘clinical evaluation’ ). Based  on its novel technology and these promising open label clinical results, 
the Relivion® DP system was granted Breakthrough Device designation by [CONTACT_941] U.S. Food and Drug 
Administration (FDA) for major depressive disorder  in August  2020 .  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 23 of 92 
 
Neurolief Confidential  
  
  
 
Summary and conclusi ons 
In summary, major depressive disorder is one of the leading causes of disability world wide . However, 
treatment options are still limited, therefore new approaches are needed to enhance clinical 
improvement. The non-invasive combined  neuromodulation o f both the occipi[INVESTIGATOR_132477] a, safe, self -administered novel technology with high potency for treating MDD patients.  
Based on  this rationale, Neurolief developed the Relivion® DP, a neuro -stimulator applying combined 
occipi[INVESTIGATOR_132478] (MDD) . Following 
completion of an early clinical study showing promising results , Neurolief designed the proposed clinical 
trial to evaluate the safety and efficacy of the Relivion® DP in a two -arms controlled, double blinded 
randomized study.  
Purpose  
The MOOD Study will evaluate the safety and efficacy   of a self -administered treatment  for MDD using an 
external combined occipi[INVESTIGATOR_132450] ( Relivion® DP). 
This pi[INVESTIGATOR_132479] (US FDA and CE) for 
Neurolief’s Relivion ®DP device.  
5. Objectives and Endpoints  
Objectives  
5.1.1.  Primary Objective  
To assess the change in  depressive symptoms, from baseline to [ADDRESS_149730] treatment initiation when 
using active external combined occipi[INVESTIGATOR_132452] ( Relivion® DP) compared to sham 
stimulation ( Relivion® DP-Sham), in subjects suffering from MDD. Depressive symptoms severity will be 
assessed by [CONTACT_132531] [ADDRESS_149731] 50% i mprovement (“responders”) in the 
HDRS [ADDRESS_149732] treatment initiation when using the Relivion® DP device  
compared to sham stimulation ( Relivion® DP-Sham), in subjects suffering from MDD.  
2. To assess the proportion of subjects achievi ng remission (HDRS 17 score ≤7) at the [ADDRESS_149733] 
treatment initiation when using the Relivion® DP device  compared to sham stimulation ( Relivion® DP-
Sham), in subjects suffering from MDD.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149734] treatment initiation 
when using the Relivion® DP device  compared to sham stimulation (Relivion® DP-Sham), in subjects 
suffering from MDD. Depressive symptoms severity will be assessed by [CONTACT_132551].  
 
5.1.3.  Safety Objective  
To demonstrate safety in using the Relivion® DP device  in subjects suffering from Major Depressive Disorder 
(MDD) . 
5.1.4.  Exploratory Objectives  
1. To assess the change on the Clinical Global Impression (CGI) scale for Improvemen t (CGI -I) and change 
on the CGI -Severity scale (CGI -S) from baseline to [ADDRESS_149735] treatment initiation when using the 
Relivion® DP device compared to sham stimulation (Relivion® DP-sham), in subjects suffering from MDD.  
2. To assess the changes in total scor e on the 16 -Item Quick Inventory of Depressive Symptomatology 
Self-Rated (QIDS -SR-16) score  from baseline to [ADDRESS_149736] treatment initiation when using the 
Relivion® DP device  compared to sham stimulation (Relivion® DP-Sham ), in subjects suffering from MDD.   
3. To assess the change in depressive symptoms from baseline to [ADDRESS_149737] treatment initiation when 
using the Relivion® DP device  compared to sham stimulation (Relivion® DP-sham ) in subjects  suffering 
from MDD. Depressive symptoms severity will be  assessed by [CONTACT_132531] [ADDRESS_149738] 50% 
reduction from baseline in their HDRS17 scale [ADDRESS_149739] Relivion® DP treatment initiation.  
2. Proportion of subjects achieving remission - defined as the percent of subjects with HDRS 17 score≤[ADDRESS_149740] Relivion® DP treatment initiation.  
3. Mean change in depressive symptoms, measured by [CONTACT_132535], from baseline to week -[ADDRESS_149741] 
treatment initiation.  
 
5.1.7.  Safety Endpoint  
Safet y of the study device following study treatment: Incidence of adverse events and serious adverse 
events related or unrelated to the study device [Time Frame: up to [ADDRESS_149742] treatment initiation].  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 25 of 92 
 
Neurolief Confidential  
  
  
5.1.8.  Exploratory Endpoints  
1. Mean Change in the severity and i mprovement scores - Clinical Global Impression scales (CGI -S and 
CGI-I) at [ADDRESS_149743] treatment initiation.  
2. Mean Change from baseline in total score of the Quick Inventory of Depressive Symptomatology self -
rated (QIDS -SR-16) score  at [ADDRESS_149744] 
Relivion® DP treatment initiation . 
 
6. Product Description  
6.1. General  
The Relivion® DP is an external neurostimulator designed for transcutaneous electrical nerve stimulation. 
The headset integrates three pairs of output electrodes which come in contact [CONTACT_132552] (two pairs) and occiput (1 pair). The electrodes d eliver the stimulation pulses produced by 
[CONTACT_132553]’s scalp. The frontal electrodes stimulate the trigeminal (supraorbital & 
supratrochlear) nerve branches and the posterior electrodes stimulate the occipi[INVESTIGATOR_132480] 
(Figur es 1 and 2 below). Stimulation intensity can be adjusted by [CONTACT_28024].  
The Relivion® DP is a prescription device that will be self -used in a home environment.  
                                  
     Figure 1: Relivion®DP and its target nerves                            Figure 2: Relivion®DP on a user  
 
The device is comprised of a headset with integrated electrodes, designed to enable stimulation of  the 
target nerves. The on -board stimulation circuit  is adapted to deliver stimulation patterns to  enhance 
proper nerve activation. The headset adjusts to various head sizes and contours and can be worn 
comfortably. Each time the headset is worn, the six electrodes are placed over the  underlying nerves.  
Four anterior forehead electrodes are aligned with branches of the trigeminal nerve (supraorbital & 

 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 26 of 92 
 
Neurolief Confidential  
  
  
supratrochlear) and two posterior electrodes are aligned with the greater  occipi[INVESTIGATOR_132480]. The 
headset includes two flexible arms that penetrate u nder the hair layers while the headset is donned.  A 
size adjustment mechanism is located at both sides of the headset.  It enables adjustment of the headset 
size to the head of the user before first use. The  Relivion® DP includes six replaceable electrode pads that 
are positioned above the integrated headset electrodes.  The pads consist of a water absorbing foam and 
should be wetted by [CONTACT_132554]. Water releasing covers are l ocated on the outer side of each occipi[INVESTIGATOR_132481].  After 
positioning the headset on the head, the user press once on the water release covers to release moisture 
from the electrode pads onto the scalp, thereby [CONTACT_132555]. The  Relivion® DP incorporates an on -board interface that enables the user to activate/deactivate the 
device and to adjust the stimulation intensity.  It also provides visual and auditory indications such as 
whether the device is active/ non-active and when there is a low battery.   
The Relivion® DP can communicate via a low energy Bluetooth link with a mobile application on the user’s 
smartphone. The dedicated mobile app is used to support the user during treatment (i.e.  
provides usage gui dance, indicates treatment duration and intensity , assists with trouble shooting  and 
uploads the data from the device to the secured cloud database ). The Relivion® DP device cannot be 
controlled (activate, adjust intensity, etc.) by [CONTACT_132556].  The patient treatment compliance 
can be monitored remotely using a dedicated secured cloud interface . 
Further details, images and specifications are provided in the User Manual.  
6.2. Proposed Mode of Action  
As explain ed, the Relivion® DP is a neurostimulator headset designed for external Combined Occipi[INVESTIGATOR_132482] (eCOT -NS). The headset integrates three pairs of output electrodes which 
come in contact [CONTACT_132557].  The electrodes deliver th e stimulation pulses 
produced by [CONTACT_132553]’s scalp.  The frontal electrodes stimulate the trigeminal 
(supraorbital and supratrochlear) nerve branches and the occiput electrodes stimulate the occipi[INVESTIGATOR_17719].  
Once signals from the trigeminal and occipi[INVESTIGATOR_132483], they converge at the 
Trigeminocervical complex and projects to key structures in the brainstem, thalamus, and cortex [27]. 
Important connections in the brainstem include the nucleus tractus solitarius (NTS) and locus coeruleus 
(LC). The NTS is a key regulator of the p arasympathetic nervous system. The LC is an important component 
of the sympathetic, or “fight and flight” nervous system, and has been implicated in neurologic and 
psychiatric conditions including major depressive disorder (MDD). The LC produces much of th e brain's 
supply of norepi[INVESTIGATOR_238] (NE) which is involved in mood and anxiety disorders  [34]. 
After the signals from these nerves pass through the brainstem, they travel to higher brain regions via the 
thalamus, and then to the primary sensory cortex and the anterior cingulate gyrus, an area thought to be 
involve d in the regulation of attention and mood. Other signals may be passed from NTS to the thalamus 
and to the amygdala, an area involved in anxiety [3]. 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 27 of 92 
 
Neurolief Confidential  
  
  
Neuroimaging studies demonstrated that trigeminal nerve stimulation increases blood flow in brain 
regions such as the anterior cingulate gyrus, that are frequently underactive in people with depression 
and anxiety disorders [8], [35], [36] . 
6.3. Dosage Form  
6.3.1.  Double Blind Phase  
For purposes of this study  double blind phase , the Relivion® DP will be provided in therapeutic and non -
therapeutic modes, to accommodate for the Active and Sham groups:  
• Active Treatment: For the therapeutic mode the device will be preset to the following parameters: 
stimulation waveform - symmetrical biphasic, phase duration 130-300 microseconds, pulse frequency 
80Hz, trigeminal stimulation intensity – up to 6 .7mA, Occipit al stimulation intensity – up to 18mA .  
• Sham Control: For the non -therapeutic mode the device will be preset to the following parameters: 
Stimulation waveform - symmetrical biphasic, phase duration [ADDRESS_149745] and study staff.  
Double blind Relivion® DP treatment will last 60±20 minutes  (preferably in two equal sessions of 30 ±10 
minutes each) per day for 5 -7 days a week (intensity level up to 50) for a period of  8±1 weeks .   
6.3.2.  Open Label Phase  
For purposes of the active open label  phase , only active treatments  will be applied with the Active 
therapeutic mode device parameters , as detailed above : stimulation waveform - symmetrical biphasic, 
phase duration 130-300 microseconds, pulse frequency 80Hz, trigeminal stimulation intensity – up to 
6.7mA, Occipi[INVESTIGATOR_132484] – up to 18mA .  
The designated study  central trainer will perform  (on site  or remote) the device conversion to the open 
label mode (i.e. conversion of the sham devices to active)  with the subjects . 
Open label phase treatment regimens would be as follows , according to the subject HDRS score at the 
end of the double -blind  phase , for a period of 8 ±1 weeks : 
Maintenance treatment  (for HDRS remitter  subjects) : 40±10 minutes 3-4 times a week (intensity level 
up to 50) .   
Daily treatment  (for HDRS responder subjects) : 5-7 days a week (intensity level up to 50) 60±20 
minutes  per day  (preferably in two equal sessions of 30 ±10 minutes each).  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 28 of 92 
 
Neurolief Confidential  
  
  
Intensified  treatment regimen  (for HDRS non-responder subjects) : 5-7 days a week (intensity level  - up 
to 60) 60±20 minutes  per day  (preferably in two equal sessions of 30 ±10 minutes each).  
The treatment regi men assignment will be re-evaluated  according to the subject HDRS score  at visit 5  
(after 4 weeks of open label treatment) . 
6.4. Manufacturer  & Device Version  
Neurolief Ltd, Israel, is the manufacturer of the Relivion® DP.  
The Relivion® DP to be used in this study is identified as follows:  
• Device version PLV3  
• SW version [IP_ADDRESS] 
• Mobile Application  Version 1.2 
6.5. Packaging & Supply  
6.5.1.  Source  
The Relivion® DP will be provi ded by [CONTACT_132558].   
6.5.2.   Labeling  
Labeling of devices will be provided in accordance with local language requirements.  
The Relivion® DP package will bear a label with the following information:  
• The name [CONTACT_132656]  
• The model marketing P/N  
• Serial number (the randomization scheme will assign each serial number to a numbered subject, such 
that the device provided will be active or sham, in accordance with the group assignment ). 
• The name [CONTACT_29773] . 
• Contact [CONTACT_648] . 
• The statement "Exclusively for SP -201 Clinical Investigation Only".  
Additional information for devices distributed in the US:  
• The statement, "CAUTION ­ Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to 
investigational use."  
Additional infor mation for devices distributed in Israel:  
• Investigator’s name  
• The statement: "Keep out of reach of children" . 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 29 of 92 
 
Neurolief Confidential  
  
  
Additionally, the label will describe all relevant contraindications, hazards, adverse effects, warnings and 
precautions, or refer the user to the  User Manual.  
6.5.3.  Storage  
The Relivion® DP will be provided to the investigational sites  and/ or be shipped to the study subjects 
directly from the sponsor dedicated warehouse . The Relivion® DP will be stored by [CONTACT_132559] a limited access area, in accordance with the storage conditions specified in the User 
Manual.  At home the subject will be requested to follow the storage requirements described in the User 
Manual.  
6.6. Intended Use & Intended Population  
The Relivion® DP external Combined Occipi[INVESTIGATOR_132449] (eCOT -NS) is intended as an 
adjunctive treatment to pharmaceutical management of for Major Depressive Disorder (MDD) in adults  
who failed to achieve satisfactory improvement from previous Antidepres sant medication treatment . The 
Relivion® DP is a prescription device for patient at home, self -use. 
6.7. Equipment  
No special equipment is required for use of the Relivion® DP.  Calibration is not required. The Neurolief App 
will be installed on a dedicated study smartphone provided to each subject  or on the subject  personal 
iPhone , if applicable .  Training will be provided as described below.  
6.8. Product Use  
Once the headset is on, the user may open the accompanying software application on the mobile p hone . 
Upon successful pairing between Relivion® DP and the application, the user follows the instructions on the 
application.  
While holding the headset’s arms away from one another, the user places the tips of the arms at the sides 
of the head (above the ea rs) and pushes the headset backwards so that the arms penetrate under the hair 
and lock to each other by [CONTACT_132560] ( Figure 3). 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 30 of 92 
 
Neurolief Confidential  
  
  
 
Figure 3: Device placement  
 
The user then presses on the water release covers located on the occip ital electrodes to release moisture 
towards the scalp.  To initiate treatment, the user presses the “+” button on the Relivion® DP.  The indicator 
light  begins flashing blue and electrical stimulus is applied. To increase the treatment intensity, the us er 
presses the “+” button until he/she feels a tingling sensation over the forehead and occiput.  
The user can further fine -tune the treatment intensity level by [CONTACT_117775] “+” or “ - “buttons . The 
treatment automatically ends after 40 minutes or alternati vely, the user can stop the treatment by [CONTACT_132561]. 
During use of the Relivion® DP the user can observe usage information via the application on the mobile 
phone.  The mobile application displays the device status and provides indications and alerts such as 
treatment intensity level, treatment duration, low battery, charging state, etc. The device cannot be 
controlled (activate, adjust intensity, etc.) by [CONTACT_132556].  
Detailed instructions for use of the Relivion® DP and the mobile app are provided in the User Manual.  
6.9. Product Training Requirements  
Investigative sites teams  will be trained on the use of the investigational device  and the treatment 
regimen by [CONTACT_132562].  Training will be conducted prior to study initi ation and throughout the study, 
as needed, and will be documented.  
Subjects will be trained on the use of the device  and the treatment regimen by [CONTACT_132563] / designee  central trainer /technical support  person . Training may be provided in a remote and/or 
in-clinic training session s prior to the first use of the device , at the beginning of the open label period and 
throughout the study, if required .  
In addition, subjects will be trained on the self -reported que stionnaires (hard copy or electronic) by [CONTACT_132564] . 

 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 31 of 92 
 
Neurolief Confidential  
  
  
During the study, technical support will be provided by [CONTACT_132565]/ designee 
central trainer / technical support person by a remote and/or in -clinic  visits ; contact [CONTACT_132566]/  technical support will be detailed in the Study Files. Training and technical support will be 
documented and maintained on file.  
6.10.  Product Receipt and Tracking  
The Sponsor will initiate shipment of equipment to the site upon receipt of all required documents (e.g., 
Institutional Review Board (IRB)/Ethics Committee (EC) approval, local regulatory authorities’ approval if 
applicable). The study dedicated central tr ainer will initiate shipment of study devices to study subjects 
upon receipt of all required documents (e.g., Institutional Review Board (IRB)/Ethics Committee (EC) 
approval, local regulatory authorities’ approval , if applicable) , completion of study site initiation visit 
activities  and only after subject’s eligibility criteria were verified by [CONTACT_977] , randomization was  
performed  and a dedicated device serial  number was assigned to the randomized subject. The Sponsor 
will maintain tracking for a ll shipment documentation.  Prior to any shipment, the site /study subject will 
be informed by [CONTACT_1034] /delegate /central trainer  on the upcoming shipment, expected arrival date, 
and content of the shipment.  The site /subject  should confirm receipt of the  shipment and maintain 
shippi[INVESTIGATOR_18220].  
Device shipments to investigational sites /study patients will be accompanied by [CONTACT_132567] y note which will 
be filed in the Study Files.  Additionally, product receipt will be documented in a Device Log which will 
document dates, quantities received, serial numbers.  
Each Relivion® DP device dispensed to  study subjects , will be documented in the  Device Accountability Log 
and Case Report Form ( CRF). 
6.11.  Product Return  
In the event of product malfunction, the subject will be asked to contact [CONTACT_132568] .  The representative will verify that the device is indeed non -func tional and will approve 
the device return /replacement to sponsor .  The representative will arrange for product 
collection /replacement and inform Neurolief and the investigational site.   
Procedures for device replacement due to device malfunction will be detailed on the study specific 
randomization and blinding plan.  
At the termination of the study, all unused study material must be returned with the corresponding 
documentation as directed by [CONTACT_132530].  All returned products from subje cts and site will be documented 
in the Device Accountability Log.   
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149746] ed that all devices will be used in the 
manner intended during the study, that they will be stored under appropriately controlled conditions and 
that they will be used only by (on) subjects who have consented to participate in the research study.  
Access to study device storage and handling should be limited to designated study staff only.  
The study dedicated central trainer and/or inves tigator  is responsible for the accountability of all used 
and unused study devices prior to dispensing them to subjects.  Device accountability records will be 
reviewed at the investigative site by [CONTACT_132569] a 
centralized fashion  on the sponsor centralized  warehouse .  Adequate device accountability records 
include documentation  of all study device received, dispensed to study subjects, returned from subject 
and returned to sponsor.  
At completion of enrollment, all devices, supplies and documentation will be reviewed and verified by [CONTACT_132570].  The site will be instructe d to return to the sponsor all study devices.  
Neurolief technical representative /central trainer will maintain records of all devices shipped to and 
returned by [CONTACT_132571] /returned due to product 
malfunction.  Final device accountability will be performed by [CONTACT_456].   
7. Study Design  
7.1. General  
This is a prospective, multi -center, 2 -arm randomized, parallel group double -blind sham -controlled 
study  followed by [CONTACT_132572] . 
The study will include the following visits & phases :  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 33 of 92 
 
Neurolief Confidential  
  
  
• Visit 1 - Screening (Day ( -14)-0) - Screening & Preliminary Eligibility Assessment.  
• Visit 2 - Baseline (Day ( -4)-0) – Eligibility, baseline assessment, Randomization to Relivion® DP vs. 
Sham control (1:1 randomization) and training.  
• Double blind phase  (Day 0 to day 56±7)- 5-7 days a week treatment: Active/Sham treatment 
protocol.  
• Visit 3 - Follow Up Visit (day 28 ±7)- MDD assessment.  
• Visit 4 - End of Doubl e-Blind phase (day 56±7)- MDD assessment.  
• Open label phase – Active treatment period:  According to HDRS response in DB phase, in between 
Maintenance  treatment 3-4 times a week and up to 5 -7 days a week of intensified treatment (Day 
56±7 to day 112±7)  
• Visit 5 - follow up visit (day 84±7)- MDD assessment.  
• Visit 6 - End of study (day 112±7)- MDD assessment and end of study.  
 
After completion of the Open label period th e subject’s participation will be over.  
The overall calculated number of subjects is   a total of  up to  124 aged 22 through 70 and an additional 
up to 36 subjects ages 18 -21.  There are no procedures for the replacement of subjects.  
The study will be conducted at a maximum of 15 investigational sites in the US and Israel ;  
Each site will enroll up to 30 subjects.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 34 of 92 
 
Neurolief Confidential  
  
  
 
 
 
Figure 4  - Study  Flowchart  

 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 35 of 92 
 
Neurolief Confidential  
  
  
Study flowchart summarized in Figure 4 and details of the assessments to be completed at each period / 
visit are provided is Section 9.  
7.2. Qualifications and Training  
The training of investigative site personnel will be the responsibility of Neurolief and site investigator.  
Training will cover topi[INVESTIGATOR_132485], study Clinical Investigation Plan (CIP, with 
reference to applicable regulations), study execution and data collection/reporting procedures specific to 
this CIP an d efficacy outcome measures rating (i.e. HDRS, MDRS, C -SSRS).  Training will be conducted prior 
to study initiation and throughout the study, as needed, and will be documented.  
Experience and training are required in order to accurately fill and assess the  Depression symptoms 
questionnaires  (i.e. HDRS, MDRS) and the C-SSRS questionnaire . Efficacy outcome measures and C -SSRS 
clinical sites raters will be required to pass the study rater training and certification program, which is 
developed to ensure adequat e scoring reliability and rating skills. These clinical sites raters would be 
blinded to the study treatment sessions data.  
It is the responsibility of the Principal Investigator [INVESTIGATOR_132486] e clinical trial (Study Coordinators, Study Nurses, Sub -Investigators, blinded raters  etc.) 
have been properly trained and included on the Delegation of Authority Log.  
7.3. Randomization   
Subjects  will be prospectively  randomized into  the clinical  study.   Randomization will  occur  only  after  the 
subject  provides informed consent, completes  all required screening  and baseline procedures, and 
satisfies  the study  eligibility  criteria .   
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 36 of 92 
 
Neurolief Confidential  
  
  
7.4. Measures to Minimize Bias  
Several measures will be implemented to minimize systematic error/bias:  
• Randomization to active treatment vs. sham control.  
• Blinding of both study subjects , site study personnel  and efficacy outcome measure raters .  
• Subjects  will be asked for their opi[INVESTIGATOR_132487].  Their response will be 
documented in the CRF.  
• Depression severity and symptoms would  be assessed according to the HDRS/MDRS and additional 
assessment tools by a qualified blinded rater, with an attempt for one rater to evaluate same subject 
through study visits.  
• Study dedicated central trainer/technical support person would be blinded to the efficacy outcome 
measure scores throughout the study .  
• Study subjects will be instructed not to di sclose any details of the treatment sessions to the study 
blinded raters during rating sessions.  
• Study subjects will be instructed to report all adverse events to the clinical site team or the central 
device trainer/technical support  but not to the blinded study rater . 
• Screening log will be completed by [CONTACT_132573].  The log will include reasons for exclusion from the study.  
• Reported serious adverse events and device related adverse events will be reviewed and adjudicated , 
if required,  by [CONTACT_132574]  ’Data Monitoring Committee ’ (DMC) 
for further review  and assessment .  The adjudicated results will be updated in the study CRF and used 
in all c ases for purposes of data analysis.  
• The sponsor, the DMC and Principal Investigator s will oversee the overall safety of the study.  The DMC 
will periodically  review safety data and will make recommendations concerning continuation, 
modification, or termination of the study.    
• Clinical monitors will verify patients’ data and ensure compliance with good clinical practice (GCP), 
CIP and other study requirements.  
7.5. Duration  
Each subject will participate in the study for up to 20 weeks  (including the screening period) . 
The duration of the treatment protocol for each subject will be 8±1 weeks of 5-7 days a week active or 
sham treatment, followed by 8±1 weeks of a maintenance treatment and up to daily (5-7 days a week ) 
treatment protocols .  The overall enrollment period is expected to last approximately [ADDRESS_149747] the MOOD  Study as part of its clinical program assessing use of the 
Relivion® DP Device .  This study is being  conducted follow ing successful completion of pre -clinical and early 
clinical studies, as summarized below.  To assess the safety and efficacy of the Relivion® DP for MDD 
patients, a sham controlled, double blinded randomized study design was chosen as most appropriate for 
meeting the study objectives.  The study includes through screening procedures which include several 
depression assessment questionnaires assesse d by a qualified rater to ensure suitability of study 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 37 of 92 
 
Neurolief Confidential  
  
  
population. Then, an in -clinic  or at -home  Relivion® DP training  will take place  to allow the subject  to operate 
the device by [CONTACT_132575] . A double -blind  5-7 days a week treatment per iod of 8±[ADDRESS_149748], followed by [CONTACT_132576] 8±[ADDRESS_149749]’s  
depression status  and response to treatment . Adverse events will be assessed and reported throughout 
the study. This study design will allow sufficient safety and efficacy data collection . 
7.6.1.  Pre-Clinical Testing  
Device Design  
The Relivion® DP has been carefully designed to perform safely and effectively its intended use as a self-
used device for the treatment of major depression in  subjects 18 -70 years  of age . The design process was 
completed in accordance with the Neurolief Quality System and is reflective of the requirements for this 
class of medical devices.  
Device Testing Summary  
Neurolief is conducting  extensive verification and validation testing of the Device .  The device is being  
tested to ensure that it provides all the capabilities necessary to operate safely and effectively. Testing 
are performed, where applicable, per guidelines established in relevant international and regulatory 
standards. Checkup  testing is currently ongoing; devices will be released for use in human subjects only 
after successful completion of relevant design verification testing.   
Following is a short outline of the various testing of the device .  
Functional testing : The tests ensure that the device meets system requirements and functional 
specifications. Mechanical durability of the various device components, verification of physical 
parameters, battery tests, hardware functionality, electrodes tests, and wireless/ra dio capability are 
tested.  
Biocompatibility testing : The tests ensure that the device is biocompatible. Irritation, sensitization, and 
cytotoxicity are tested for both the headset and electrode pads. The biocompatibility tests are performed 
per ISO [ZIP_CODE] (ISO [ZIP_CODE] -5: Biological Evaluation of Medical Devices - Part 5: Tests for in Vitro Cytotoxicity; 
ISO [ZIP_CODE] -10: Biological Evaluation of Medical Devices – Part 10: Tests for Irritation and Delayed -Type 
Hypersensitivity).  
Software validation : Software (SW) validation is performed on the Relivion® DP software to verify that the 
developed software complies with the defined SW requirements and demonstrates the actual 
implementation of risk mitigation as analyzed in the risk analysis. SW validation is being perfo rmed 
according to FDA GPSV (Guidance Principles of Software Validation) and IEC62304 Software Development 
Life Cycle standard. The device SW is a “moderate” level of concern (LOC) as defined in FDA’s Guidance 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 38 of 92 
 
Neurolief Confidential  
  
  
for the Content of Premarket Submission for Sof tware Contained in Medical Devices (May 11, 2005) 
(“Software Guidance Document”).  
Electromagnetic compatibility and electrical safety : Electromagnetic testing for the device is conducted 
by [CONTACT_132577] [ZIP_CODE] -1-2, Medica l electrical equipment - Part 1 -2: 
Collateral Standard: Electromagnetic compatibility – Requirements and tests and IEC [ZIP_CODE] -1-11, Medical 
Electrical Equipment – Requirements for medical electrical equipment and medical electrical systems used 
in the home healthcare environment.  
Electrical safety testing of the device is conducted by [CONTACT_132578] [ZIP_CODE] -1, Medical Electrical Equipment, Part 1: General requirements for basic safety and essential 
performance. Further, electrical equipment testing with particular requirements for the safety of nerve 
and muscle stimulators are conducted in accordance with IEC [ZIP_CODE] -2-10, Medical Electrical Equipment: 
Part 2 -10: Particular Requirements for the Safety of Nerve and Muscle St imulators.  
7.6.2.  Clinical Evaluation  
Overview  
Neurolief has gained clinical experience through the conduct of a series of clinical studies during the 
design and development phases of the Relivion ®- a device similar to the Relivion® DP, indicated for 
Migraine , as well as  of the Relivion® DP device .  
In the f ollowing are short summaries of clinical research performed  with the Relivion ® and the Relivion ®DP 
device s: 
 
First -in-Human Study (study # 100CLD ): A prospective, randomized, single blind, parallel -group, placebo 
controlled clinical study to evaluate the short -term effectiveness of eCOT -NS in reducing migraine related 
pain.  Forty subjects were enrolled at a single investigational site in Israel and t reated using an earlier 
design iteration of the Relivion ®, out of which 10 were excluded due to protocol exclusion criteria or 
inability to coordinate an intervention meeting, leaving a total of 30 subjects , 15 who received real 
stimulation and 15 who received placebo (sham) stimulation.   
The average reduction of Pain Visual Analogue  Scale (VAS) score , the study’s primary endpoint,  in the 
treatment group was 79.2% compared to an increase of 14.9% in the contro l group, amounting to a 94.1% 
difference between the two study groups at the end of treatment (P=0.0002). The difference between the 
groups was substantially greater than anticipated in the original hypothesis which assumed only a 20% 
difference. The secon dary endpoints also revealed substantial differences between the groups with clear 
superiority of the treatment group. At two hours post treatment, eight subjects (53.3%) in the treatment 
group were pain free compared to none in the control group (P=0.0031 ). Twelve subjects in the treatment 
group (80%) were "Responders" compared to only two in the control group (16.7% ; P=0.0018). The 
number of subjects with “Sustained pain free" and “Sustained responders" at [ADDRESS_149750] treatment 
was also substantially hi gher in the treatment group compared to the control group (P<0.05), reflecting 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149751] treatment, 
only five subjects (33.3%) in the treatment group had functional disabi lity compared to twelve subjects 
(100%) in the control group (p=0.0004). Only two subjects (13.3%) in the treatment group had 
photophobia two hours post treatment compared to nine subjects (75%) in the control group (P=0.0020). 
A superiority of the treatme nt group was also found in the "Global impression of treatment" (P=0.0192) 
reflecting patient’s satisfaction from the treatment. Nausea and phonophobia showed a favorable trend 
in the treatment group but did not reach statistical significance due to the re latively small number of 
subjects who suffered from these symptoms.  
Only one mild adverse event (mild dizziness) was reported during the trial and was resolved without any 
treatment.  
Importantly, t hese results are mostly superior to those reported by [CONTACT_132579].  
Altogether, these results indicate that the Relivion ® is a safe and effective abortive treatment for epi[INVESTIGATOR_132488] a superior,  fast acting, and adverse -reaction free alternative to medications.  
 
Pi[INVESTIGATOR_132489] -[LOCATION_002] (OUS) Study (study # SP301 ):  
In a prospective randomized, parallel -group, sham -controlled clinical trial, [ADDRESS_149752] treatment initiation. Pain intensity (VAS) was 
recorded before treatment and then at 1, [ADDRESS_149753] treatment  initiation. Following one -hour 
of treatment, pain decreased significantly more in the treatment group compared to the sham group at 
all time points (group difference at 1 -hour 41%, p=0.0002, at 2 -hours 33%, p=0.03, at 24 -hours 36%, 
p=0.02). Headache relie f rate (subjects who improved from severe or moderate pain at baseline to mild 
or no pain) was significantly higher in the treatment group compared to the sham group at 1 -hour (66.7% 
vs. 26.32%, p=0.01) and 2 -hours (76.19% vs. 31.58%, p=0.01) test points. Responder rate (≥ 50% pain 
reduction) was significantly higher in the treatment group than in the sham group at 1 -hour (67% vs. 20%, 
p=0.001), 2 -hours (67% vs. 32%, p=0.02) and 24 -hours (78% ver. 48%, p=0.04). Pain freedom at 2 -hours 
for subjects with a se vere -moderate baseline pain level was significantly higher in the treatment group 
than in the sham group (43% vs. 11%, p=0.02). Notably, pain freedom at 2 -hours regardless of baseline 
level was more than twice as high in the treatment group compared to the  sham group but did not reach 
statistical significance (41.7% ver. 20%, respectively, p=0.12). No serious adverse events were reported.  
Pi[INVESTIGATOR_132490] (study #SP302) :  
Findings from an additional pi[INVESTIGATOR_22735], multi -center, placebo -controll ed clinical trial (RIME) of the Relivion® 
system were submitted to the US Food and Drug Administration (FDA) for review in late 2020. This study 
included [ADDRESS_149754] -
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 40 of 92 
 
Neurolief Confidential  
  
  
treatment was found significantly higher in the active group than in the sham group (60% vs. 37%, p -value 
0.0180 ) with a therapeutic gain of 23% . Pain free at [ADDRESS_149755] -treatment was found significantly higher 
in the active group than in the sham group  (46.0% ver. 11.86%, p-value<.0001) with a therapeutic gain of 
34.14%. Improvement in MBS at [ADDRESS_149756] -treatment was also significantly higher in the active group 
than in the sham group (80.56% ver. 60.0%, p -value=0.0466) with a therapeutic gain of 20.56%. MBS 
freedom at [ADDRESS_149757] -treatment was also statistically significantly higher in the active group than in the 
sham group (75% ver. 46.67%, p -value=0.0099) with a therapeutic gain of 28.33%. Complete symptoms 
free (Pain Free and Freedom from MBS) at [ADDRESS_149758] -treatme nt was found statistically significantly 
higher in the active group than in the sham group  (47.22% ver. 11.11%, p -value=0.0003) with a therapeutic 
gain of 36.11%. In terms of rescue medication intake, a statistically significant difference was found 
betwee n the two study groups, as 29.17% of subjects in the active group consumed rescue medication on 
their first eligible epi[INVESTIGATOR_132491]. 52.63% in the sham group, p -value=0.0152.  In relation to consistency of 
response, the proportion of subjects who were pain free  in at least 50% of their treated epi[INVESTIGATOR_1841] [ADDRESS_149759] -treatment was statistically significantly higher in the active group than in the sham group (44% ver. 
15.25%, p -value=0.0009). 2 -24 hours pain free rate was statistically significantly higher in the a ctive group 
than in the sham group s (36% ver. 8.47%, p -value=0.0004) with a therapeutic gain of 27.53%. Adverse 
event incidence was similar in both study  groups and no serious adverse events were reported.  
This multi -center pi[INVESTIGATOR_132492] -
administered, combined occipi[INVESTIGATOR_132493]® device is a safe and 
effective treatment for migraine.   
Major Depression  related Clinical Data to Date  
A prospective, sing le group, open label feasibility clinical trial  (study #SP200) : this study  assessed the 
safety and efficacy of the Relivion ®DP in patients with MDD. The study included unipolar MDD patients 
who had 1 -6 antidepressant medication trials fail prior to entering the study. Treatment consisted of 1 -2 
hours of daily self -administered sessions. The primary endpoint was change in the Hami lton Depression 
Rating Scale (HDRS -17) score at 6 weeks compared to baseline. During treatment, data from the device 
was gathered via a mobile app installed on the patients’ cellphones and uploaded to a secure cloud 
database for analysis. In this pi[INVESTIGATOR_30396], 23 MDD patients ranging in age between 21 -65 years, completed 
the study protocol. Six weeks of daily treatment resulted in a 9 -point average improvement in HDRS -17 
score (P<0.05). 35% (8/23) and 70% (16/23) of the patients improved ≥50% and ≥40% in the  HDRS -[ADDRESS_149760] (35%) of the patients reached remission (8/23). Additional results 
included a mean improvement of 9 points on the Hamilton Anxiety Rating Scale (HAMA -A) and a mean 
improvement of 6 points on the Quick Inventory of Depressive Symptomatology (QIDS -SR). No serious 
adverse events were observed. All participants were able to self -administer the treatment in their home 
with a high compliance rate.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 41 of 92 
 
Neurolief Confidential  
  
  
8. Selection of Subjects  
8.1. Study Population  
The study will include male and female subjects, 18 to  70 years of age; Primary diagnosis by [CONTACT_9288] -V 
criteria for MDD.  
8.2. Subject Enrollment  
The overall calculated number of subjects is a total of [ADDRESS_149761] will sign a written or electronic  informed consent 
form (ICF) that has been ap prov ed by [CONTACT_132580]/ EC of the respective clinical 
site or the central IRB/EC, during the screening visit . Written  or electronic , informed  consent will be 
obtained for all patients who are potential study candidates prior to applying any study specific 
assessment to the subject or any data collection .  See Section 9.[ADDRESS_149762] is considered enrolled (randomized)  in the study when it is determined that all 
inclusion/exclusion criteria are met during visit 2, the informed consent  was signed and all the required 
depression assessment  questionnaire s were  completed as detailed  in section 7.1.2 . Enrolled  subjects  will 
receive  (a) the study device , (b) the device  application which may  be installed on the subject 's phone (or 
on a dedicated iPhone  supplied by t he Sponsor ) (c) instruction s for use including the  treatments  regimen . 
Also , at this visit subjects will  undergo device and device app , treatment regimen and Patient Reported 
Outcome (PRO) (hard copy and/or electronic) t raining and will be asked to complete the self-reported 
depression questionnaire s and blinding assessment  questionnaire (hard copy or electronic) . Device and 
device app training will be performed by [CONTACT_132581] . All subject’s training activities  
may be performed by [CONTACT_63689] -site or remote fashion. In the case of a remote device training the device 
would be sent by a courier to the subject home and only then the device training would take place . Upon 
training completion subject would initia te the study daily treatment. During  the DB period ( 8±1 week  from 
device training ), Subjects will follow  the provided treatment regimen  which specifies their recommended 
daily treatment regimen, recommended  stimulation  duration and maximal intensity . Subjects will return 
for follow up visits , which may be performed  by [CONTACT_63689] -site or remote fashion, at 4±[ADDRESS_149763] visit 2 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 42 of 92 
 
Neurolief Confidential  
  
  
(visit 3) and at 8±[ADDRESS_149764] visit 2 (visit 4). During visits [ADDRESS_149765]’s  depression symptoms will be 
assessed by [CONTACT_132582]-reported  
questionnaire . Study visit  [ADDRESS_149766]’s  compliance with the treatment regimen  during the DB phase will 
be assessed . Subjects who would  not fulfill the minimum stimulation requirements  during  the DB phase 
(non-compliant subjects ) will com plete their participation in the study . DB phase t reatment  regimen  
compl iant subjects will be offered to participate in a 8+1 week s open -label period with an active device. 
Subjects who choose  to continue to the open label phase will be trained as per their recommende d 
treatment  regimen  (see Figure 5) by [CONTACT_132583] -site or remote fashion. (regardless 
their prior DB treatment assignment)  and will follow this treatment regim en for the next 4-8±1 weeks . 
Subjects will return for follow up visits (on-site or remote) at 4±[ADDRESS_149767] visit 4 (visit 5) and at 8±[ADDRESS_149768] visit 4 (visit 6). During visits [ADDRESS_149769]’s depression symptoms will be assessed by [CONTACT_132584] (electronic or hard copy) using the study questionnaires . At study visit 
5 the subjects response to treatment, according to HDRS , will be re -evaluated and treatment regimen 
may be amended accordingly (see Figure 5 ), re -training will be performed by [CONTACT_132585] , if 
required . Study visit 6 will be the end of  study visit  during which the device will be returned, final data will 
be collected,  and the subjects will be exited from the study .  
Subjects found ineligible by [CONTACT_132586] 'screen failure' on the 
screening & enrollment log and will not take part in the study. Screen failure subjects will not be included 
in the intention -to-treat analysis, nor will they be counted as part of the target subject sample number .   
8.3. Inclusion Criteria  
In order to be included in the MOOD study patients must fulfill all the inclusion criteria.  
1. Males and females 18  -70 years of age :  
a. Up to 124 randomized subjects aged 22 -70. 
b. Up to 36 randomized subjects aged 18 -21. 
2. Primary diagnosis of unipolar major depressive disorder  by [CONTACT_2681] -V criteria.  
3. Current MDD epi[INVESTIGATOR_132453] . 
4. Score on the Hamilton Depression Rating Scale (HDRS 21) > 20 
5. Symptoms of current major depressive epi[INVESTIGATOR_132454], as determined by [CONTACT_737], for the 
current epi[INVESTIGATOR_132455] (ATRF) or 
Antidepressant Treatment Intolerance Form (ATIF):  
• Did not respond or have insufficiently responded by [CONTACT_21316] 50% improvement; dose and durati on 
defined & rated at minimum confidence level 3 on the ATRF;  
• Did not respond or has insufficiently responded to at least one but no more than four adequate trials 
of antidepressant medications (4 ≥ ATRF ≥1) or  
• Did not respond or has insufficiently res ponded due to poor tolerability to at least two inadequate 
antidepressant medication trials (ATIF ≥2).  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149770] one (1) antidepressant medication (minimum therapeutic dose not 
required if tolerability precluded further dose titration) an d is willing to remain on the same daily dose 
of antidepressant medication(s) for a minimum of [ADDRESS_149771] receiving current depression focused psychotherapy: psychotherapy initia ted at least [ADDRESS_149772] has cognitive and/or motor skills needed to operate a smartphone and can be contact[CONTACT_54407] , as determined by [CONTACT_737] . 
8.4. Exclusion Criteria  
To be included in the MOOD  study , patients must fulfill none of the exclusion criteria.  
1. History of intracranial surgery .  
2. Current denervation one or more of the follows: the supraorbital or supratrochlear branches of the 
trigeminal nerve, or the greater occipi[INVESTIGATOR_132494] n erve.  
3. An implanted neurostimulators or any implanted metallic or electronic device in the head, a cardiac 
pacemaker or an implanted or wearable defibrillator, except for dental implants.  
4. Skin lesion , scars,  or inflammation at the region of the stimulating electrodes.  
5. Subjects with a history of traumatic brain injury (TBI), defined as a disruption in the normal function 
of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury, within 
3 months of study enrollment.  
6. Pregn ancy or Lactation.  
7. Women  of reproductive age not using a reliable contraceptive  method , as determined by [CONTACT_3786] . 
8. In the opi[INVESTIGATOR_689], subjects with a psychiatric history consistent with, suspi[INVESTIGATOR_271], 
or diagnostic of, bipolar de pression or depression associated with psychosis.  
9. Borderline personality disorder, defined by [CONTACT_2681] -V criteria, that in the judgement of the Investigator 
is likely to complicate the assessment of clinical response to study treatments or limits the patient’s 
ability to comply with study procedures . 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 44 of 92 
 
Neurolief Confidential  
  
  
10. Subjects who, within one (1) year of study enrollment, have a history consistent with, suspi[INVESTIGATOR_132495], any of the following: psychosis, psychotic disorder, schizophrenia or schizoaffective 
disorder,  in the opi[INVESTIGATOR_689].  
11. Subjects who demonstrate or have a history of any cognitive disorder or impairment, memory loss, 
dementia, confusion or delirium that, in the opi[INVESTIGATOR_689], may compromise the integrity 
of the study data o r impact the ability of the subject to comply with the study requirements.  
12. Past 12 months active suicidal intent or plan as defined by a “yes” answer to Q4 or Q5 on the 
Columbia -Suicide Severity Rating Scale, (C -SSRS) or, with a history of suicide attempt  in the past twelve 
months.  
13. Subjects currently (past month) meeting diagnostic criteria for Obsessive -compulsive disorder or post -
traumatic stress disorder and that is their primary diagnosis  
14. Subjects meeting the DSM -V criteria for alcohol use disorder or other substance use disorder (not 
including tobacco/nicotine) within six (6) months prior to study enrollment.   
15. The subject has any past or present medical condition, disease, illness, disorder or injury that, in the 
opi[INVESTIGATOR_689] , may reduce or hinder the subject’s ability to fully comply with all study 
requirements for the duration of the study or may confound the integrity of the study data.  
16. Participation in a previous study with the Relivion® DP  or the Relivion  ® device.  
17. Treatment with Transcranial Magnetic Stimulation (TMS)  in the past 6 months.  
18. Current treatment with any other approved or investigational brain stimulation therapi[INVESTIGATOR_014] (i.e. Vagus 
or trigeminal nerve Stimulation, tDCS, TES) . 
19. Failure to receive clini cal benefit from an adequate trial of ECT in the current or a past depressive 
epi[INVESTIGATOR_132458] . 
20. Subject having received Botox treatment in the head or neck  region within [ADDRESS_149773] having received s upraorbital or occipi[INVESTIGATOR_132496] 1 month prior to enrolment.  
22. Head circumference smaller than 51 centimeters or larger than 60 centimeters.  
23. Current neurological condition or disease which, in the opi[INVESTIGATOR_871], is likely to 
manifes t a depressive syndrome or symptoms that would substantially confound the diagnosis or 
serial assessment of major depressive disorder.  
24. Subjects participating in other clinical trials evaluating experimental treatments or procedures.  
 
8.5. Vulnerable Population  
No vulnerable population will take part in this study.  
  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 45 of 92 
 
Neurolief Confidential  
  
  
9. Study Procedures  
9.1. Schedule of Events  
The schedule of events is depi[INVESTIGATOR_28071] 1  and Figure 4.   
Table 1: Schedule of Events  
Visit  1 Visit 1 
Day   -14-0 Visit 21 
Day -4 -0 Visit 3 
Week 4+1 Visit 4  
Week 8+1 Visit 5  
Week 12+1 Visit 6 
Week 16+1 
Event  Screening   
Randomization  Double blind phase - 
Daily Treatment  open label extension phase  
Event / Visit window  Day -14-0  
Day -4-0 Day 28 ±7  Day 56±7 Day 84±7 Day 112±7 
Written /electronic  Informed Consent  X      
Preliminary Eligibility Assessment  
(SCID)  X      
Medical history & Demography  X X     
Concomitant medication  X X2 X2 X2 X2 X2 
Suicidal intent assessment  (C-SSRS )  X X X X X 
ATRF/ATIF  X      
Eligibility assessment  X X     
Depression symptoms questionnaires (HDRS, 
MADRS, QIDS - SR -16, CGI-S&CGI -I)   
X X X X X 
Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q -LES-Q)  X  X  X 
Pregnancy urine test3 X      
Enrollment & Randomization   X     
Device training  (on site or remote)   X   X 4 X 4  
Device conversion (Sham → Active) & OL 
treatment regimen training      X   
Blinding assessment  questionnaire   X     
Device logs verification5  X  X  X 
Active / sham DB treatment6   X X   
Open label extension treatment6     X X 
Subject impression questionnaire        X 
Adverse events   X X X X X 
End of study     X7  X 
1 visit 1 & 2 can be performed same day  
2 change  in concomitant medications /medical history  
3 For women of childbearing potential only  
4 Optional  
5 Device logs – Remotely  
6 weekly QIDS -SR-16 
7 For treatment regimen non-compliant patients  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 46 of 92 
 
Neurolief Confidential  
  
  
9.1.1.  Visit 1  – Screening (Day -14- 0) Screening and Preliminary Eligibility 
Assessment.  
Written below are the assessments to be completed at Visit 1  (either on site or remotely) :  
• Written \Electronic  informed consent.  
• Assignment of subject ID and EDC registration . 
• Preliminary Eligibility Assessment by [CONTACT_941] S tructured Clinical Interview for DSM -IV axis I disorders  
(SCID ). 
• Subject’s current and past (e.g. if failed) antidepressant medication treatments (including ATIF, ATRF 
forms)  
• Medical history & Demography.  
• Urine pregnancy test (for women of childbearing potential).  
9.1.2.  Visit 2 – Baseline (Day -4 - 0) Eligibility evaluation , Randomization 
and device training .  
Written below are the assessments to be completed at Visit 2 (either on site or remotely) :  
• Eligibility assessment . 
• PRO training  for subjec ts self-reported  questionnaire  (QIDS -SR-16 and Q -LES-Q) (hard copy and/or 
electronic)  
• Depression symptoms questionnaires:  
o By [CONTACT_132587]: HDRS21 (HDRS17 - removing [ADDRESS_149774] questions from the HDRS21), MDRS, 
CGI-S & CGI -I 
o By [CONTACT_1130]: QIDS -SR-16, Q -LES-Q. Subject self -reported questionnaire may be filled in 
electronically (ePRO) or by [CONTACT_132588]  
• Document change in antidepressant medication, if any .  
• Documented significant change in health status, if any . 
• Suicidal intent assessment by [CONTACT_92142]  (C-SSRS) . 
• A review the study requirements with the subject to help ensure compliance.   
• Randomization to Active Treatment or Sham Control.  
• Subject will be provided with the device and the cellular app installed either on their personal iP hone 
or on a dedicated study iPhone, as applicable . Device and cellular iPhone, if required, may be provided 
to the subject at the site  (in the case of an on -site visit) or by [CONTACT_132589] (in the case of a remote visit ) 
• Device training  will be performed by [CONTACT_3433] e study central trainer and may be performed  during an on -
site visit or in a remote fashion.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149775]  will read the User manual , the quick guide and  will watch the instructional video and 
be trained on the device and recommended treatment regimen  (detailed on the Relivion® DP 
Quick guide)  by [CONTACT_132590]  (on-site or remote) . 
o Device size will be adjusted to subject head circumferences.  
o Subject wi ll self -practice the device along with the mobile application to become familiar with 
its use and with the stimulation  sensation . 
• Blinding Assessment questionnaire  (by [CONTACT_132591] (ePRO)   
• Adverse events occurring during the visit will be do cumented . 
Study visit [ADDRESS_149776] him/her. This requirement will be described in the Informed Consent Form (ICF) . 
The study central trainer  may contact [CONTACT_132592]/her to follow the 
recommended daily treatment regimen.   
9.1.3.  Daily treatment period  (Day 0- day 56±7) 
• Subjects will operate the device along with the dedicated mobile application independently at home  
or surrounding , according to the recommended treatment regimen provided by [CONTACT_132593] “Relivion® DP quick guide” for 8±1 consecutive weeks . The Relivion ®DP programmed treatment 
duration will be 40 minutes. The daily treatment (duration and intensity ) will be gradually  increased  
up to a full effective treatment of 60±20 minutes , 5-7 days a week . In general,  it is expected that the 
recommended  daily treatment  time would be performed in two equal time sessions  per day  (e.g. 
morning and evening , each of about 30±10 minutes ). During a treatment session, if necessary, 
treatment can be paused by [CONTACT_132594].  Subjects will continue t heir daily 
treatment up to their scheduled visit 4 day. 
• Subject will self -complete the QIDS -SR-16 once every 7 days starting from day 0  (electronic or hard 
copy) . 
• Study  central trainer  will periodically verify device logs on the study cloud database and may contact 
[CONTACT_132595] -training, if required.  
• Study team and central trainer will contact [CONTACT_132596]/her to use the 
device , If necessary.   
• The summary of each subject study treatments will be indicated on the subject binder . 
• During this period, subject will be asked to schedule  2 follow -up evaluation visits.  
9.1.4.  Visit 3 – 4 weeks Follow up  (Day 28±7) 
Written below are the assessments to be completed at Visit 3 (either on site or remotely) :  
• Depression symptoms questionnaires:  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 48 of 92 
 
Neurolief Confidential  
  
  
o By [CONTACT_132587]: HDRS21 (HDRS17 - removing [ADDRESS_149777] questions from the HDRS21), 
MDRS, CGI -S & CG I-I 
o By [CONTACT_1130]: QIDS -SR-16. Subject self -reported questionnaire may be filled in 
electronically (ePRO) or by [CONTACT_132588] . 
• Suicidal intent assessment by [CONTACT_92142] (C -SSRS)  
• Change in concomitant medications , if any . 
• Significant change in health status, if any . 
• Adverse events will be documented . 
9.1.5.  Visit 4 – end of the DB phase  (Day 56±7)  
Written below are the assessments to be completed at Visit 4 (either on site or remotely) :  
• Depression symptoms questionnaires:  
o By [CONTACT_132587]: HDRS21 (HDRS17 - removing [ADDRESS_149778] questions from the HDRS21), 
MDRS, CGI -S & CGI -I 
o By [CONTACT_1130]: QIDS -SR-16, Q -LES-Q. Subject self -reported questionnaire may be filled in 
electronically (ePRO) or by [CONTACT_132588] . 
• Suicidal intent assessment by [CONTACT_132597] (C -SSRS)  
• Change in concomitant medications , if any .  
• Significant change in health status, if any . 
• Adverse events will be documented.  
• The characteristics of each subject study treatments regimen will be indicated on the subject 
binder.  
•  At the end of the double -blind treatment phase treatment compliance would be verified as 
follows:  
o A stimulation session marked as “Pass” if a minimal  average  intensity  of 25 on the Relivion ®DP app 
(i.e= Minimal average stimulation of 2.57mA Trigeminal, and 6.92mA  Occipi[INVESTIGATOR_132497] ), was delivered.     
o The first treatment week (Ramp Up) will not be counted for treatment compliance.  
o Expected treatment time  for total DB phase : A total of 2400 minutes  of “pass” treatment  time  
(calculated as a scenario of 80 min per day, 5 days a week for 6 weeks).  
o Minimal patient compliance for the DB treatment period will be regarded as 70% compliance to 
the above  cumulative “pass” stimulation time recommendation.  
• DB treatment regimen compliant subjects will be offered  to continue t o the open label extension phase 
for additional 8±1 weeks.  
• Treatment regimen non-compliant  subjects will exit the study  and return the device and iPhone , if 
provided . For these subjects this study visit woul d be the “end of study visit” . 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 49 of 92 
 
Neurolief Confidential  
  
  
• Once the OL treatment regimen allocation  will be decided, the central trainer will contact [CONTACT_1560] (on site or remote) to perform the device conversion to the open label mode (i.e. 
conversion of all devices  to active  mode ), train the subjects on the assigned treatment regimen 
and re -train on the device use, if required .  
• OL treatment regimens would include:  
o Maintenance treatment (for remitters): 40±10 minutes 3 -4 times a week (intensity level up to 50)   
o Daily treatment (for responders): 5 -7 days a week (intensity level up to 50) 60±20 minutes per day 
(preferably in two equal sessions of 30±10 minutes each).  
o Daily  Intensified treatment regimen (for non -responders): 5 -7 days a week (intensity level up to 
60) 6 0±20 minutes per day (preferably in two equal sessions of 30±10 minutes each).  
• Study visit [ADDRESS_149779] would continue 
his/her previous treatment regimen up until the day of the device conversion to the open label mode. 
The device conversion day wo uld be considered as the first day of the OL treatment phase . 
• Subjects  which completed the minimal stimulation time required by [CONTACT_132598] . 
9.1.6.   Open label extension phase (Day 56±7- day 112±7) 
• According to their visit 4 HDRS  response  assessment, subjects  will be assigned into one of three  
open label  treatment  groups: Remitters /Responders/ Non responders  as follows :  
o Remitter s: HDRS ≤7 at study visit 4 (week 8±[ADDRESS_149780] treatment  initiation ). 
o Responder s: 50% ≥ HDRS score improvement from baseline  at study visit 4  (week 8±[ADDRESS_149781] 
treatm ent initiation) . 
o Non -responder s: all other subjects who are not remitters  or responders  (50% <HDRS score 
improvement from  baseline ) at study visit 4 (week 8±[ADDRESS_149782] treatment initiation).  
See Figure 5: Open label phase study flow . 
 

 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 50 of 92 
 
Neurolief Confidential  
  
  
Figure 5: Open label phase study flow  
• Subjects will operate the device along with the dedicated mobile application independently at 
home or surrounding, according to the recommended treatment regimen provided by [CONTACT_132599] “Relivion® DP quick guide” for 8±1 consecutive weeks. The Relivion ®DP device 
program med treatment duration will be 40 minutes. If needed, (i.e. for originally sham subjects 
who are not used to the active stimulation sensation) the daily treatment (duration and intensity) 
will be gradually increased up to a full effective treatment accordin g to the assigned treatment 
regimen (i.e. for remitters, responders and non -responders) . In general, it is expected that the 
responders and non -responders’ subjects recommended daily treatment time of 60 ±20 minutes  
would be performed in two equal time sess ions per day (e.g. morning and evening, each of about 
30±10 minutes). The remitters subjects would apply the stimulation once a d ay 3-4 times a week 
for 40+[ADDRESS_149783] and then be resumed.  
Subjects will continue their assigned treatment  regimen  up to their scheduled visit 5 day.  At study 
visit 5 the subjects response to treatment, according to HDRS, will  be re -evaluate d and treatment 
regimen may be amended accordingly (see Figure 5 ), re -training will be performed by [CONTACT_132600], if required . The subjects will continue their assigned treatment regimen up to their 
scheduled visit 6 day (end of study).  
• Subject will  continue to  self-complete the QIDS -SR-16 once every 7 days.  
•  The characteristics of each subject  assigned  study treatments  regimen , both from visit 4 and visit 5 (if 
applicable ), will be indicated on the subject binder . 
•  Study central trainer will periodically verify device logs on the study cloud database and may contact 
[CONTACT_132595] -training, if required.  
•  Study team and central trainer will contact [CONTACT_132601] , If 
necessary.  
• During this period, subjec t will be asked to schedule  2 follow -up evaluation visits  (on-site or remote) . 
9.1.7.  Visit 5 – 12 weeks Follow up (Day 84±7) 
Written below are the assessments to be completed at Visit 5 (either on site or remotely) :  
• Depression symptoms questionnaires:  
o By [CONTACT_132587]: HDRS21 (HDRS17 - removing [ADDRESS_149784] questions from the HDRS21), 
MDRS, CGI -S & CGI -I 
o By [CONTACT_1130]: QIDS -SR-16. Subject self -reported questionnaire may be filled in 
electronically (ePRO) or by [CONTACT_132588].  
• The subjects ’ respo nse to treatment, according to HDRS, will be re -evaluated and treatment 
regimen may be amended accordingly as specified in section 9.1.6 and Figure 5 .  
• The central trainer will provide training to the subjects on the newly assigned treatment regimen, 
if ap plicable.  
• Clinically significant current suicidal intent re -assessment by [CONTACT_92142]  (C-SSRS)  
• Change in concomitant medications  will be documented .  
• Adverse events will be documented.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 51 of 92 
 
Neurolief Confidential  
  
  
9.1.8.  Visit 6 – end of study  (Day 112±7)  
Written below are the assessments to be completed at Visit 6 (either on site or remotely) :  
• Depression symptoms questionnaires : 
o By [CONTACT_132587]:  HDRS21 (HDRS17 - removing [ADDRESS_149785] questions from the HDRS21), 
MDRS, CGI-S & CGI-I 
o By [CONTACT_1130]: QIDS -SR-16, Q-LES-Q. Subject self-reported  questionnaire  may be filled in 
electronically (ePRO) or by [CONTACT_132588]  
• Clinically significant current suicidal intent re -assessment by [CONTACT_92142] (C-SSRS)  
• Change in concomitant medications  will be documented.  
• Adverse events will be documented.  
• Subject Impression will be documented by [CONTACT_132602] . 
• Central trainer will arrange the  collection  of the device and the iPhone, if applicable , from the 
subjects  and final accountability will be performed . 
• The summary of each subject study treatments will be indicated on the subject binder.  
•  At this point subject’s participation in this study will be over . 
•   Adverse Events that are still ongoing will be followed  according to section 9.9 
9.2. Activities Performed by [CONTACT_2728]’s Personnel  
A sponsor representative, such the study manager/monitor may be p resent at the clinic  for overseeing 
and guiding the study screening, enrollment and  follow up procedures.   
The representatives’ activities will occur in such a way that they do not influence the conduct of the study, 
nor do they interfere with any medical decisions or bias the data integrity.  Additionally, they will be 
described in the Informed Consent Form (ICF)  and sponsor technical support list.  
Device  management and training will be conducted on a centralized fashion by [CONTACT_132603] s. The central trainers’  responsibilities may include:  
 
• Operational duties such as: Dispensing of the blinded Relivion® DP devices to the subjects according 
to the randomization scheme and arranging their collection back to sponsor.  
• Following up on subject’s  treatment compliance throughout the study  
• Presence at study visits (on site or remotely ) for supporting the study participants in device 
training and operation .  
• Presence at the clinic/remotely for observing the use of the device and gathering information and 
feedback from the site personnel.  
• Arra nge the conversion  of the Sham devices to Active ones at the start of the O L extension.  
• Provide device technical support to subject throughout the study conduct.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 52 of 92 
 
Neurolief Confidential  
  
  
9.3. Prior and Concomitant Medications  
Prior to study enrollment visit, subjects will be on a stabl e dose of Antidepressant medication s (type and 
dose) for at least four weeks , as per subjects’  medical records  or subject self-report . During the study 
period, the subject will continue his/her Antidepressant medication treatment  on the same type an d dose 
throughout the study . Please see section 9.7 for additional details . During  every study visit, t he study team 
will document patient’s Antidepressant medication  (type  and dose ).  
9.4. Subject Consent  
Informed consent will be obtained b efore any study -specific procedures are initiated or data collected. 
Principal Investigator [INVESTIGATOR_022]/her authorized designee will conduct the informed consent process.  
At the screening visit, subjects will be approached to obtain written or electronic infor med consent prior 
to any data collection. Once the ICF is collected, screening of subject will follow. The purpose of the study 
and the benefits and risks of the procedures will be explained to the subject and the consent process must 
be documented accordi ngly in the medical record. Subjects who agree to study participation must sign a 
Sponsor and IRB/EC -approved  ICF. Consent to participate in this study must be given in writing  or 
electronically . Subjects that are unable to give consent will not be included in study.  
Informed Consent will be obtained in accordance with the CFR Title 21, Part 50 (US) or ISO14155:2011 
(Israel) as well as the Declaration of Helsinki  and will follow the FDA guidance  for the use of electronic 
informed consent .  
Electronic measures in order to o btain informed consent  remotely will be supplied to all study sites and 
will be implemented in the study EDC system with accordance to the FDA guidelines  for the use of 
Electron ic Informed Consent  [37] 
The Investigator or designee must obtain written /electronic  informed consent before any clinical study 
related activity takes place. Prior to entry into the study, the IRB/ EC and Neurolief -approved  ICF form, and 
the Health Insurance Portability and Accountability Act (HIPA A) Authorization Form (US only) will be given 
to each subject. The Investigator or designee will fully inform the subject of all aspects of the clinical study 
that are relevant to the subject’s decision to participate in the clinical study (e.g. purpose an d duration of 
the study, requirements of the subject during the study, potential risks and possible benefits associated 
with participation in th is study). All items addressed in the Informed Consent Form must be explained. 
The language used shall be as non -technical as possible and must be understandable to the subjects.  
The subject must have ample time and opportunity to read and understand the Informed Consent Form, 
to inquire about details of the clinical study, and to decide whether or not to participa te in the clinical 
study. All questions about the clinical study should be answered to the satisfaction of the subject. In the 
case that a subje ct is unable to read, an impartial witness must also be present and sign the informed 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149786]’s questions have 
been answered.  
Neither the Investigator, nor the investigation si te staff shall coerce or unduly influence a subject to 
participate or to continue to participate in the clinical study. The informed consent process shall not waive 
or appear to waive the subject’s rights.  
When the subject decides to participate in the cl inical study, the HIPAA Form (US only) and the Informed 
Consent Form must be personally signed and dated by [CONTACT_423] .  
After all persons have signed and dated the Informed Consent Form, the Investigator  or designee  must 
provide the subject with a copy.   
Neurol ief will inform the Investigators whenever information becomes available that may be relevant to 
the subject’s confirmed participation in the clinical study. The Investigator or his/her authorized designee 
should inform the subject in a timely manne r.  
Neurolief will revise the written Informed Consent Form whenever new information becomes available 
that may be relevant to the subject’s confirmed participation in the clinical study. The revised information 
will be sent to the Investigator for approva l by [CONTACT_1201]/EC. After approval by [CONTACT_1201]/EC, a copy of this 
information must be provided to the participating subjects, and the informed consent process as 
described above needs to be repeated.  
If the ICF is amended during the course of the study, the I RB/EC will determine:  
• Whether or not active subjects should be re -consented at their next visit and  
• Whether or not subjects who have completed the study at the time of the amendment should repeat 
the informed consent process.  
Subjects will be informed that qualified personnel from the investigational center, the Sponsor 
(Neurolief ), agencies such as the  FDA/local regulatory authority in Israel  and/or the IRB/EC may have 
access to clinic records that reveal their identity.  
The investigational center  must report the following deviations  to their IRB/EC:  
• Failure to obtain informed consent from subject.  
• Failure to obtain informed consent prior to performing one or more study procedures.  
• Failure to maintain ICFs on file for all subjects who have provided informed consent.  
• Use of an ICF that has not received approval from the IRB/EC.  
• Use of an incorrect v ersion of the ICF.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149787]  provides informed consent, completes  all required screening  and baseline procedures, and 
satisfies  the study  eligibility  criteria . Eligible subjects will be randomly allocated (with a 1:1 ratio) to one 
of the following 2 treatment groups based on a randomization scheme using the permuted block method 
stratified by [CONTACT_384]:  
• Active stimulation.  
• Sham stimulation.  
The randomization scheme  will be prepared by [CONTACT_132534] (version 9.4.) random 
number procedure. The block size will be random, and all study personnel will therefore be blinded to the 
randomization block size.  Only  the unblinded statistician  /sponsor un blinding party  and designates  will 
be privy  to the masked  randomization  scheme.  
The Relivion® DP Active and Sham devices will look the same and will be provided in the same packaging 
bearing the same labeling.  Hence, both subjects and study personnel will remain blinded to the assigned 
treatment group.    
9.6. Unblinding  
9.6.1.  Planned Unblinding  
Subjects and study personnel may be unblinded to each subject’s group assignment at the end of the 
study.  Blinding will be opened,  and the subject will be notif ied about his/her treatment assignment , if 
requested .  
9.6.2.  Unplanned Unblinding  
The investigator, sponsor or regulatory authorities may initiate unplanned unblinding procedures in the 
interest of patient safety .   
In case of medical emergency, the Investigator  will contact [CONTACT_1034]’s on call unblinded biostatistician 
and the specific patient’s code will be broken. In case the sponsor’s on -call unblinded biostatistician 
cannot be reached, the investigator will contact [CONTACT_132604]’s code will be broken. The Investigator will promptly document the reason for breaking the code.  
9.7. Medication Compliance  
For the double -blind  phase duration, subjects will  be asked to maintain  on a stable type and dose of 
antidepressant medications  (any psychotropic  medications with CNS effects that are prescribed or taken 
for MDD symptoms) .   
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 55 of 92 
 
Neurolief Confidential  
  
  
A change of up to 25% ( increase or decrease ) in dose of an ongoing psychotropic medication would be 
considered as “no change ” i.e stable dose .    
A change in the type of an ongoing psychotropic medications  and/or  discontinuation  of medication 
regimen or a change of dose over 25% (decrease or increase)  of an ongoing psychotropic medication 
throughout the study , would be considered as a “change” i.e.  non stable -dose . 
If necessary  (i.e. In the case of emergence or worsening  of insomnia ), benzodiazepi[INVESTIGATOR_1651] <3mg lorazepam 
(or equivalent dose of another benzodiazepi[INVESTIGATOR_050] ) may be used for agitation/anxiety or insomnia up to 3 
times per week. Par tial benzodiazepi[INVESTIGATOR_132498], including zolpi[INVESTIGATOR_6730] 5 to 10 mg/day, zaleplon 5 to 10 
mg/day, and eszopi[INVESTIGATOR_11123] 2 -3 mg/day, may be used on an exceptional basis for insomnia/sleep disturbance 
within the prescribing doses for insomnia. Any equivalent short half -life non -benzodiazepi[INVESTIGATOR_132499], zaleplon, or eszopi[INVESTIGATOR_132500] .  
During the open label  phase ineffective antidepressant doses may  be decreased , as per investigator 
discretion . 
9.8. Assessment of Efficacy  
Efficacy parameters including Hamilton Depression Rating Scale -HDRS17 and HDRS 21; Montgomery -
Asberg Depression Rating Score  (MDRS ); Quick Inventory of Depressive Symptomatology -QIDS -SR-16; 
and Clinical Global Impression scales -CGI-S and CGI -I; will be p erformed and documented at each visit.  
The study  questionnaires  will be documented by a qualified rater ( HDRS , MDRS ), C-SSRS , CGI-S and CGI -I 
using the hard copy  questionnaires  and thereafter will be documented in  the subject ’ CRF.  
The study questionnaires th at are self - reported by [CONTACT_748] (QIDS -SR-16, Q-LES-Q, SIQ) will be  
completed using the study EDC ePRO tool or hard copy .  
The treatment duration and intensity will be documented automatically in the device logs.  
9.9. Assessment of Safety  
Safety will be assessed by [CONTACT_132605]. Type, incidence, severity, duration, and procedure/device relationship of adverse events (AEs) will 
be collected throughout the study. Subjec ts with AEs at study exit  will be followed for [ADDRESS_149788]. Adverse event data will be collected and reported on eCRFs.  
Additionally , at baseline  and during each visi t (from randomization  throughout the study ) and whenever 
there is a suspect for increased suicidal intent , the investigator team  will perform  the Columbia -Suicide 
Severity Rating Scale (C-SSRS)  questionnaire with  the subject  for the  assessment of suicidality . At baseline, 
subjects that in the past 12 months reported active suicidal intent or plan as defined by a “yes” answer to 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149789] twelve months will be 
excluded (according to exclusion  criteria # 12). Throughout the study, a n answer of "yes" to Q 4 or Q5 
would  serve  as an immediate need for re assessment  with the principal investigator . Upon principal 
investigator [INVESTIGATOR_132501] “yes” answer  to Q4 or Q5, the patient would be excluded  from the study  
and the event will be reported as an AE .  
9.10.  Data  Capture  
Data will be collected using a hard copy CRF and/or  Electronic Data Capture (EDC) System for all site 
reported information .  
Data points not collected and/or recorded will be considered deviations unless otherwise specified. 
Procedures used for data review, database cleaning, and issuing/resolving data queries will be included in 
the data management plan .  
The Principal Investig ator must ensure the accuracy and completeness of the recorded data and then 
provide his/her signature [CONTACT_132657]/ eCRFs. The Investigator’s electronic signature [CONTACT_132658].  
Visual  and/or computer data review will be performed to identify possible data discrepancies. Manual 
and/or automatic queries will be created in the EDC system and will be issued to the site for appropriate 
response. The site staff will be responsible for resolv ing all queries in the database.  
This study will be using a [ADDRESS_149790] not been followed.  Deviations are classified by [CONTACT_132606] ( i.e., sporadic vs. repeated) 
and seriousness ( i.e., major vs. minor ).  Major deviations may impact subject  safety, alter the risk/benefit 
ratio, compromise the integrity of the study primary end point data .  Minor deviations do not impact 
subject  safety, compromise the integrity of the primary end point study data .  
No changes to the protocol will be permitted. Investigators are required to obtain prior approval from the 
sponsor or designee and their respective IRB/EC and Regulatory Authority, if required, before initiating 
deviations from the protocol, except where necessary to protect the rights, safety and wel l-being of 
human subjects  in an emergency.  Such approval will be documented in writing and maintained in study 
files.  The investigator must notify Neurolief and the reviewing IRB/EC of any deviation, which will be 
recorded in the eCRF, from the CIP when specific to the protection of the life or physical well -being of a 
subject in an emergency. Such notice must be given as soon as possible, but in no event later than 5 
working days after the emergency has occurred . Prior approval is generally not expected in situations 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 57 of 92 
 
Neurolief Confidential  
  
  
where unforeseen circumstances are beyond the investigator’s control, ( e.g., subject  did not attend 
scheduled follow -up visit); however, the event is still considered a deviation and must be recorded in the 
subject  eCRF.  
Deviations shall be r eported to the sponsor  regardless of whether medically justifiable, pre -approved  by 
[CONTACT_132530] , IRB/EC  and Regulatory Authority, if required , or taken to protect the patient in an emergency. 
If these  deviations affect the scientific soundness of the CIP or the rights, safety, or welfare of human 
subjects the IRB/EC will also be notified. All other deviations will be reported per the site’s IRB/EC 
deviation policy.  All protocol deviations will be reported in the eCRF.  Non -subject  specific deviations ( e.g., 
unauthorized use of an investigational device outside the study, unauthorized use of an investigational 
device by a non -certified physician) must also be reported by [CONTACT_132607].  
Investigators mus t also adhere to procedures for reporting study deviations to their EC /IRB  in accordance 
with their specific EC /IRB  reporting policies and procedures.  
The monitor will discuss deviations with relevant site personnel and will document them on monitoring 
visit reports.  
Neurolief will review records of deviations and will consider the need for corrective and preventive action 
and further external reporting to regulatory authorities.  Deviations will be summarized and included in 
the study report.  Assessment and discussion of their potential impact / lack of impact on study results 
will be addressed.  
If the deviation is performed without written approval from all parties, the investigator may be terminated 
from the study. Corrective and preventive actions and principal investigator [INVESTIGATOR_132502]/or Monitoring Plan. If further escalation is needed, it 
may result in Corrective and Preventive Action (CAPA), suspension, or termination. If it is determine d that 
there is investigator fraud, or strong evidence of fraud, the course of action may include, but is not limited 
to: potential exclusion from analyses, site closure, notification of the responsible IRB/EC of the actions to 
be taken, notification of ke y stakeholders and/or study team of the actions to be taken, notification of 
appropriate regulatory authority(ies) and/or restrictions on future participation in clinical studies.  
9.12.  Subject Withdrawal or Discontinuation  
The reason for study exit, including screen failure, will be documented on the applicable CRF/ eCRF and in 
the subject file. The Sponsor must be informed of each withdrawal case.  
Once a subject has been enrolled in the study, he/she may withdraw his/her consent to participate in the 
study at any time without prejudice.  Participation in this clinical investigation is entirely voluntary . 
In the event the subject withdraws consent during the study, the date of withdrawal will be documented. 
Individual subjects will not be replaced.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149791] from the study at any time for the following reasons:  
• Severe side effects clearly related to the study procedures .  
• Presence or appearance of exclusion criteria  
• Clinically significant current suicidal intent as assessed by [CONTACT_92142] : a “yes” answer to Q4 
or Q5 on C -SSRS questionnaire . 
• Appearance of accompanying diseases rendering further participation in the study impossible  
• A significant protocol deviation , as determined either by [CONTACT_132608] .  
• Subject noncompliant with procedures  
• Subject noncompliant with visits  
• At the specific reasonable request of the Investigator  
Attempts will be made to conduct an exit/final visit prior to a subject terminating participation in the 
study.  The reason for early discontinuation will be documented in the source documents and eCRF . Data 
collected up to the point of withdrawal or premature discontinuation will be included in the data analysis, 
unless specifically requested not to.   
9.13.  Subject Missed Contact / Visit  
Every attempt will be made to contact [CONTACT_132609] . If a subject does 
not show for a visit and cannot be contact[CONTACT_132610] -up information, he/she will be counted as 
a ‘missed visit’ for t hat specific schedule. Prior to counting the subject as a ‘missed visit’ the following will 
be performed:  
• Repeated attempts to contact [CONTACT_132611].  Each attempt should be clearly 
documented in the source documents and the response o r lack thereof should be captured . 
• Repeated, documented attempts to contact [CONTACT_423] ’s general practitioner or referring physician.  
• If a visit cannot be arranged, obtain as much information as possible through all communication 
means with the subject and/or his/her treating physician.  
If still unsuccessful to obtain information, attempts shall be made to contact [CONTACT_132612]. A subject will be considered 'lost' only after a period of two (2) weeks after the last 
scheduled visit for that subject . If a subject is lost, the methods used to attempt to contact [CONTACT_132613].  At least three attempts  should be made to contact [CONTACT_3184]/or his/her treating 
physician via all available routes, and a certified letter should be sent to the permanent address on file.  A 
copy of the letter and return or delivery receipts should be retained in the subjec t’s source document . 
The Sponsor should be notified and the End of Study (EOS) form should be completed.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 59 of 92 
 
Neurolief Confidential  
  
  
10. Risks and Benefits  
Risk management is performed as per ISO [ZIP_CODE], complete documentation is maintained on quality 
management file (Neurolief document #  QAD -222).  
10.1.  Potential Risks  
Technical characteristics and electrical output of the Relivion® DP are similar to other known external 
transcutaneous devices  applying electrical stimulation for psychiatric purpose .  Safety of the  Relivion® DP 
has been extensively tested and confirmed through bench performance testing as well as throughout 
Neurolief’s early clinical study .  No serious  device related adverse events were recorded during  the early 
studies, and treatment was well tolerated by [CONTACT_39370].  
Current study design does not require application of electrical stimulation for exceptionally prolonged 
periods, or other circumstances where the use of the device has not yet been validated.  Hence this 
protocol presents minimal risks to the subje cts and adverse events are not anticipated beyond those 
reported for other electrical neurostimulation devices.  Potential expected device side effects are 
summarized below . See Section  11.2 . 
No information is available for use of the Relivion® DP during  pregnancy  or lactation , so women who are 
pregnant or lactating are not eligible for inclusion in this study.  
Participating in this study DB phase means that the subject has a 50% chance of receiving a sham 
treatment , which may lead to worsening  of the subject Depression state  (including suicid al intent ). 
The above mentioned risk is mitigated by [CONTACT_716]: study patients  continu e using their prescribed 
antidepressant medication s during the study duration  and are closely followed up by [CONTACT_132614], including the continued assessment of their MDD severity on the HDRS score , weekly 
QIDS -SR-[ADDRESS_149792] arm and/or respond immediately with treatment change  
and if required study exit . In the case of worsening depression symptoms,  a process for emergency 
unblinding is implemented during study conduct.  In addition, subjects and family members would be 
instructed to contact [CONTACT_132615].  
The risk for suicide is reduced by [CONTACT_132616] a current suicidal 
intent  or plan would not be randomized to the study  (exclusion criteria  #12: Past 12 months active suicidal 
intent or plan as defined by a “yes” answer to Q4 or Q5 on the  Columbia -Suicide Severity Rating Scale, (C -
SSRS) or  with a history of suicide attempt in the past twelve months ). In addition,  at every follow up visit 
the suicidal intent  will be re -assessed  and documented by [CONTACT_3476] . Throughout the study, an 
answer of "yes" to questions Q 4, or Q5 would exclude  the subject from the study.  
There may be additional risks related to this study (other than those listed here) that are not yet known.  
Risks must be continuously monitored, assessed,  and documented by [CONTACT_737] . 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 60 of 92 
 
Neurolief Confidential  
  
  
10.2.  Potential Benefits  
Neurolief’s feasibility  clinical study demons trates a significant improvement effect of the Relivion® DP in 
subject’s  who suffers from MDD  by [CONTACT_132617] 9 points on the HDRS score  over the six weeks 
of treatment period .  Moreover, 35% of the patients showed symptoms remission  and 85 % experien ced 
a decreas e in their HDRS score with no serious adverse effects  over the six weeks of treatment period . It 
is anticipated that patients will experience similar effect under the setting of the current study.  
Another known benefit to pati ents participating in such a study is the ability to learn more about their 
medical condition through the assessments that will be performed throughout the course of the study.  
Additionally, patients will be closely observed by [CONTACT_132618] .  Last, all assessments associated with the study, as well as the study device, are provided at no charge 
to the part icipants.  
The information from this study may benefit other subjects with Major depression  in the future . 
10.3.  Risk Control and Mitigation  
The following efforts will minimize risks to subjects in the study:  
• Conduct of the study following successful completion of extensive bench performance testing and 
careful risk analysis.  
• Selection of investigators who are experienced and skilled in management of patients with MDD . 
• Establishment of a training program for study staff members (investigators and coord inator) and use 
of tools that will ensure proper training to the subjects for home use of the device.  
• Clearly defining the inclusion and exclusion criteria such that only appropriate patients are enrolled 
in the study.  
• Close monitoring of worsening of depr ession symptoms and suicidal intent  
10.4.  Risk-Benefit Rationale  
Assessing the risks against the potential benefits of the use of the Relivion® DP for improvem ent of MDD  
symptoms , Neurolief and the principal investigators have determined that there is a high like lihood that 
the expected benefit may outweigh the risk in patients fulfilling the study eligibility criteria.  
11. Adverse Event s and Device Deficiencies  
Adverse event definitions used in this study are based on ISO [ZIP_CODE]: 2020  (Clinical Investigation of Medical 
Devices for Human Subjects -- Good Clinical Practice ).  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 61 of 92 
 
Neurolief Confidential  
  
  
Adverse Events will be collected for all enrolled subjects with the point  of enrolment  (Visit #2 upon 
randomization ) and end at the study termination visit (visit # 6). Subject s with AEs at termination visit  will 
be followed for [ADDRESS_149793].  
During the course of the study, all AEs will be collected and reported on the CRF/ eCRF  including :  
• All AEs related to Relivion® DP device and/or procedure .  
• All AEs not related  to Relivion® DP device and/or procedure . 
• All device deficiencies that may lead to a SAE .  
• All Deaths  
11.1.  Definitions  
Safety definitions are provided below.  Clinical events to be considered and reported as AE or SAE inclu de 
but are not limited to those listed in Section 11.2.  
Adverse Event (AE):  Any untoward medical occurrence, unintended disease or injury, or untoward clinical 
signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related 
to the investigational medical device  and whether anticipated or unanticipated . 
NOTE [ADDRESS_149794] (ADE):  Adverse event related to the use of an investigational medical device.  
Note 1: This definition includes adverse events resulting from insufficient or inadequate instructions for 
use, deployment, implantation, installation, or operation, or any malfunction of the investigational 
medical device.  
Note 2: This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device.  
Serious Adverse Event (SAE): An adverse event that  led to any of the following : 
• death;  
• a serious deterioration in the heal th of the subject , users, or other persons as defined by [CONTACT_132619]:  
‐ a life -threatening illness or injury;  
‐ a permanent impairment of a body structure or a body function  including chronic diseases ; or 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 62 of 92 
 
Neurolief Confidential  
  
  
‐ in-patient or prolong hospi[INVESTIGATOR_059];  or 
‐ medical or surgical intervention to prevent life threatening illness or injury or permanent 
impairment to a body structure or a body function;  
‐ fetal distress, fetal death , a congenital abnormality or birth defect  including physical or mental 
impairment . 
 
Note:  A planned hospi[INVESTIGATOR_5912] -existing condition, or a procedure required by [CONTACT_132620], without a serious deterioration in health, is not considered to be a serious adverse event.  
Serious Adverse Device Effect (SADE): Adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event.  
Unanticipated (Serious ) Adverse Device Effect  (U(S)ADE): Serious adverse device effect which by [CONTACT_47720], incidence, severity or outcome has not b een identified in the current risk assessment , or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of 
subjects .  
11.2.  Relivion®DP Anticipated Adverse Events  
Possible risks and adverse events that ma y be associated with the Relivion® DP device are based on  adverse 
events reports of similarity devices include, but are not limited to the following:  
• Unpleasant sensation during treatment  
• Scalp Numbness sensation during and after treatment  
• Persistent tingling sensation after the treatment ends  
• Pain  in the head and neck area  
• Skin reaction (for example, irritation, lesion, burn) beneath the stimulation electrodes . In this case, 
treatment sho uld be temporarily discontinued.  
• Redness of the skin under or around the electrodes. Skin redness usually disappears within several 
hours after treatment . 
• Sleepi[INVESTIGATOR_008], fatigue or sleep disorders  
• Sedative effect during or after treatment  
• Dizziness during or after treatment  
• Tension type headache after treatment  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149795] 
be recorded in the source document and eCRF, irrespective of attribution to device or procedure. All 
clearly related signs, symptoms, and abnormal findings should be grouped under one diagnosis.   A 
description of the event, including the  start date, resolution date, action taken, and the outcome should 
be provided, along with the investigator’s assessment of the severity, the seriousness and the relationship 
between the AE and the study device  and/or procedure .  If any radiological imagin g or other testing are 
taken, which are related to the event, these will be added to the eCRF of the subject . 
11.3.2.  Hospi[INVESTIGATOR_132503] a 
serious adverse event unless s pecifically instructed otherwise in this protocol.  Any condition responsible 
for surgery should be documented as an adverse event if the condition meets the criteria for an adverse 
event.   
Neither the condition, hospi[INVESTIGATOR_059], nor surgery are reported a s an adverse event under the following 
circumstances:  
• Hospi[INVESTIGATOR_30896] a preexisting condition.  
• Emergency department visits, unless meeting the SAE definition under another criterion.  
• Social admission (e.g. , patient has no place to sleep).  
• Administrative admission (e.g., for yearly physical exam).  
• Optional admission not associated with a precipi[INVESTIGATOR_10244] (e.g., for elective 
cosmetic surgery).  
• Nursing home admission, admission to custodial care, or admission to a rehabilitation facility.  
11.3.3.  Reporting Procedures  
The investigator shall submit to the sponsor and to its representative all associated information and 
documentation related to each AE.  Notification to local authorities shoul d follow local requirements.  
AEs will be categorized according to severity and relatedness.  
Adverse Event Severity Classification  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 64 of 92 
 
Neurolief Confidential  
  
  
Severity of AEs will be determined using the following scale:  
• Mild: The subject  is aware of a sign or symptom, but it is easily tolerated . 
• Moderate: Discomfort or interference with usual activity . 
• Severe: Incapacitating, with inability to engage in usual activity . 
Relatedness:  The investigator will determine the relationship of each adverse event to the use of the 
device / procedure.  
Adverse Event Relationship Classification  
Causality assessments define the relationship between the use of the medical device (including the 
medical procedure) and the occurrence of each adverse event. During causality assessment activity, 
clinical judgment shall be used and the relevant documents, such as the Clinical Evaluation Report and the 
Risk Management Report shall be consulted, as all the foreseeable serious adverse events and the 
potential risk s are listed and assessed there. The presence of confounding factors, such as concomitant 
medication/treatment, the natural history of the underlying disease, other concurrent illness or risk 
factors shall also be considered.  
Each AE will be classified ac cording to five different levels of causality. The Sponsor and the Investigators 
will use the following definitions to assess the relationship of the serious adverse event to the medical 
device or procedures:  
Relationship to study product administration w ill be determined as follows:  
Not related:  relationship to the device or procedures can be excluded when:  
• the event is not a known side effect of the product category the device belongs to or of similar devices 
and procedures;  
• the event has no temporal r elationship with the use of the device or the procedures;  
• the serious event does not follow a known response pattern to the medical device (if the response 
pattern is previously known) and is biologically implausible;  
• the discontinuation of medical devic e application or the reduction of the level of activation/exposure 
- when clinically feasible – and reintroduction of its use (or increase of the level of 
activation/exposure), do not impact on the serious event;  
• the event involves a body -site,  or an orga n not expected to be affected by [CONTACT_41491];  
• the serious event can be attributed to another cause (e.g. an underlying or concurrent illness/ clinical 
condition, an effect of another device, drug, treatment or other risk factors);  
• the event does not depend on a false result given by [CONTACT_132621], when applicable;  
• harms to the subject are not clearly due to use error;  
• In order to establish the non -relatedness, not all the criteria listed above might be met at the s ame 
time, depending on the type of device/procedures and the serious event.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 65 of 92 
 
Neurolief Confidential  
  
  
Unlikely:  the relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by [CONTACT_5748], but additional information may be obtained.   
Possible:  the relationship with the use of the device is weak but cannot be ruled out completely. 
Alternative causes are also possible (e.g. an underlying or concurrent illness/ clinical condition or/and an 
effect of another device, drug or treatment). C ases where  relatedness cannot be assessed or no 
information has been obtained should also be classified as possible.  
Probable:  the relationship with the use of the device seems relevant and/or the event cannot reasonably 
be explained by [CONTACT_5748], but additional information may be obtained.  
Causal relationship:  the serious event is associated with the device or with procedur es beyond reasonable 
doubt when:  
• the event is a known side effect of the product category the device belongs to or of similar devices 
and procedures;  
• the event has a temporal relationship with device use/application or procedures;  
• the event involves a b ody-site or organ that  
‐ the device or procedures are applied to;  
‐ the device or procedures have an effect on;  
• the serious event follows a known response pattern to the medical device (if the response pattern is 
previously known);  
• the discontinuation of me dical device application (or reduction of the level of activation/exposure) 
and reintroduction of its use (or increase of the level of activation/exposure), impact on the serious 
event (when clinically feasible);  
• other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an effect of 
another device, drug or treatment) have been adequately ruled out;  
• harm to the subject is due to error in use;  
• the event depends on a false result given by [CONTACT_132621], when applicable;  
• In order to establish the relatedness, not all the criteria listed above might be met at the same time, 
depending on the type of device/procedures and the serious event.  
 
The Sponsor and the Investigators will distinguish between the AEs rela ted to the device and those related 
to the procedures (any procedure specific to the clinical investigation). An adverse event can be related 
both to procedures and the device. Complications of procedures are considered not related if the said 
procedures w ould have been applied to the subjects also in the absence of device use/application.  
In some particular cases the event may be not adequately assessed because information is insufficient or 
contradictory and/or the data cannot be verified or supplemented . The Sponsor and the Investigators will 
make the maximum effort to define and categorize the event and avoid these situations. Where the 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 66 of 92 
 
Neurolief Confidential  
  
  
Sponsor remains uncertain about classifying the serious event, it should not exclude the relatedness and 
classify the event as “possible”.  
Adverse Event Outcome Classification  
Adverse Event Outcome Classification will be  defined according  to the following: 
Resolved:  The event has fully resolved at the end of the study.  
Resolved with sequel:  The event has resolved, but retained pathological conditions resulting from the 
prior disease or injury.  
Continuing:  The event is ongoing at the end of the study.  
Death:  This event is determined to be the cause of death.  
11.3.4.  Reporting of Adverse Events  
Pleas e refer to Table [ADDRESS_149796] of the minimum AE reporting requirements for Investigators. If local 
regulations or IRB/EC require faster reporting, then the Investigator will adhere to those requirements. 
Reporting of all safety events to the Sponsor will b e completed through Investigator submission of the AE 
CRF by e -mail  and/or eCRF in the remote data capture (RDC) system. In case of emergency only for SAEs 
(ex. RDC system is unavailable), the sponsor site representative  may be contact[CONTACT_43417]; this will not 
serve as a substitute for proper reporting on the appropriate eCRF.  
 
Table 2: AE Reporting Requirements  
Type  Report to  Reporting Timeframe (from time of 
learning of event)  
Adverse Event (AE)  Sponsor  Within 10 working days  
IRB/ EC Per EC reporting requirements  
Serious Adverse Event (SAE)  Sponsor  Within 24 hours  
IRB/ EC Per/IRB/  EC reporting requirements  
Adverse Device Effect (ADE), Serious 
Adverse Device Effect (SADE) and 
Unanticipated Serious Adverse Device 
Effect ([LOCATION_003]DE /UADE ) 
 Sponsor  Within 24 hours  
IRB/ EC Per EC reporting requirements  
 Sponsor  Within 48 hours   
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 67 of 92 
 
Neurolief Confidential  
  
  
Type  Report to  Reporting Timeframe (from time of 
learning of event)  
Device Deficiency  IRB/ EC If SAE occurs due to the device 
deficiency, within 24 hours of 
learning of the event and per EC 
reporting requirements  
EC Per EC reporting requirements  
 
Events will be reviewed by [CONTACT_132622]/EC. Reporting will occur within the timelines per local regulations and 
requirements.  The Principle Investigator is responsible to report the events to t he IRB/ EC. 
The sponsor shall immediately conduct an evaluation of any unanticipated events if determines that the 
event presents an unreasonable risk to subjects, report the results of such evaluation to the Regulatory 
authority and to reviewing IRB/EC and participat ing investigators within [ADDRESS_149797] receives notice of the event.  
11.3.5.  Notification to Authorities  
The following events are generally considered reportable during the course of this study and should be 
reported to the Sponsor:  
• any SAE  
• any Device Deficiency that might have led to an SAE if  
‐ suitable action had not been taken or  
‐ intervention had not been made or  
‐ if circumstances had been less fortunate  
• new findings/updates in relation to already reported events.  
• deaths  
Events will be reviewed by [CONTACT_132623]. Reporting to  
the sponsor or its designated CRO is responsible for relaying adequate informatio n on reportable events 
to the regulatory authorities per country’s applicable reporting requirements.  
11.3.6.  Device Deficiencies  
Device deficiency is an inadequacy with respect to the device’s identity, quality, durability, reliability, 
usability, safety, or perf ormance, such as a malfunction, failure, use error and inadequa cy in the 
information supplied by [CONTACT_132624]. Device deficiencies may or may not be 
associated with an adverse event.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149798] led to an SAE if a) suitable action had not been taken or b) intervention had not been 
made or c) if circumstance had been less fortunate, will be documented within 24 hours  of knowledge .  If 
possible, the device(s) associated with a malfunction or failure should be retained until arrangements for 
its collection are made by [CONTACT_132530] . 
Device deficiencies are NOT to be reported as AEs. However, if there is an AE that results from a device 
deficiency, that specific event would be recorded on the appropriate eCRF.  
A device deficiency must be reported to Neurolief  (technical support) within 48 hours after the 
investigator is made aware of the event.  
Device deficiencies will be summarized and reported in the clinical study report and will be reported to 
the regulatory authorities per country’s applicable reporting requirements.   
11.3.7.  Safety Monitoring and Adjudication of Adverse Events  
The sponsor will review submitted AE information and may request supplemental information if needed. 
For SAE, U (SA)DE and ADE (as classified by [CONTACT_093]) a narrative will be prepared and adjudicated 
for assessing the relatedness, seriousness and possible action items required.  The sponsor may as k for 
further information or clarification from the investigator. A summary of the adjudication results will be 
issued; if different than investigator’s report, PI [INVESTIGATOR_10718],  and the information will be forwarded to 
Neurolief medical advisor for fin al adjudication. All the safety data including any adverse events or side 
effects related to the treatment will be reported periodically to the independent data monitoring 
committee (DMC)  as indicated in section 14.[ADDRESS_149799] 
the integrity of the study.  
Adjudicated events will serve as a basis for reporting AE/SAE.  Differences between site -reported events  
and adjudicated events will also be presented and discussed in the report.   
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 69 of 92 
 
Neurolief Confidential  
  
  
12. Statistical Considerations  
12.1.  Study Design and Objectives  
12.1.1.  Objectives  
The MOOD Study will evaluate the safety and efficacy of a self -administered treatment for MDD using 
an external combined occipi[INVESTIGATOR_132504] ( Relivion® DP). 
12.1.2.  Study Design  
This is a prospective, randomized, double -blind, parallel -group, sham controlled, multi -center clinical 
investigation  followed by [CONTACT_132625] . All enrolled patients are those treated 
with the Relivion® DP device either by [CONTACT_132626]. The treatment will be done 
according to the IFU. Patients duration in the study will be up  to  20 weeks (including the screening period).  
 
One interim analysis is planned after 86 (~80% of the calculated sample size ) evaluable subjects have been 
accrued,  mainly for sample size re -assessment. The primary, as well as the safety endpoints will be 
assessed in the ITT, mITT , PP and mYITT  analysis sets.  
After the last treated patient will complete full study duration, a final clinical study report will be 
gener ated with conclusions relating back to original objective(s) and hypothesis/hypotheses.  
12.2.  Study Endpoint Variables  
12.2.1.  Primary endpoint variable  
The primary endpoint is the change in HDRS17 total score  from baseline to [ADDRESS_149800]’s baseline 
HDRS17 score from the score at visit  4. 
12.2.2.  Secondary and exploratory endpoint variables  
The secondary endpoints of responder and remission will be represented in the f orm of binary variables 
which will be assigned the value of “1” if the subject is a “responder” or a “remitter” per specific secondary 
endpoint, and “0” otherwise. Other exploratory binary endpoints will be defined in a similar manner.  
Secondary and explor atory endpoints described as changes from baseline, such as QIDS -SR-16, CGI-S and 
CGI-I and MDRS will be calculated by [CONTACT_132627]’s baseline score from the score at each visit.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 70 of 92 
 
Neurolief Confidential  
  
  
12.2.3.  Safety endpoint variables  
Incidence of all adverse events and complications by [CONTACT_132628].  
12.3.   Study Hypothesis  
Null hypothesis:  
Mean change from baseline in HDRS17 total score to [ADDRESS_149801] treatment initiation in subjects 
suffering from Major Depressive Disorder (MDD) in the active Relivion® DP arm = Mean change from 
baseline in HDRS [ADDRESS_149802] treatment initiation in the sham arm.   
Alternative hypothesis:  
Mean change from  baseline in HDRS [ADDRESS_149803] treatment initiation in subjects suffering 
from Major Depressive Disorder (MDD) in the active Relivion® DP arm ≠ Mean change from baseline in 
HDRS17 to [ADDRESS_149804] size of 0.5 (Cohen’s d - Cohen, J. (1988). Statistical power analysis for the behavioral sciences 
(2nd ed.) Hillsdale, NJ: Lawrence Earlbaum Associates.) is considered a moderate effect size, and is lower  
than effect sizes seen for similar studies, thus 0.[ADDRESS_149805] size to be detected.  
In a company feasibility study of the Relivion® DP device we evaluated the me an change from baseline up 
to weeks 3 and 6 in HDRS -17 score. The 3 week results were a (baseline adjusted) mean change of -5.95 
points (95% CI:[ -8.1,-3.8]) and the standard deviation of 4.2 points. The 6 week results were a (baseline 
adjusted) mean change  of -8.4 points (95% CI:[ -10.6, -6.26]) and the standard deviation of 5.[ADDRESS_149806] size (Cohen’s D) of 0.5 (and 
assuming equal group variances rounded up to 5 and 6 at 3 and 6 weeks respectively) we would expect 
an HDRS17 score reduction in the sham group of about 3.45 points at 3 weeks and 5.4 points at 6 weeks 
unless the treatment arm has a greater reduction.  
In planning their study, Levkovitz et al (Brainsway ltd.)  assumed that e ffect size of 0.[ADDRESS_149807] size of 0.76. Neuronetics Inc. reported an HDRS17 score reduction of 5.2 
points in the active TMS group compared with a 3.3 point reduction in the sham group (ES>0.5), with a 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149808] size of 0.4. Moreover, in a l arge analysis of the FDA database of  antidepressant 
medications, Khan et al reported that the mean percentage reduction from the baseline in HDRS17 score 
was 40.7% for active treatment and 30.9% for placebo.   
We use conservative estimates of a 3.[ADDRESS_149809] deviation of 6 points. Calculations 
show that a sample size of 53 subjects per group (total 106) would provide 80% power at a 5% level of 
significance (two -sided) to detect the difference between treatment and sham groups.  
Given our preliminary results, together with other companies clinically relevant data, we hypothesize that 
our statistical assumptions are aligned with competitive treatments for MDD . 
The company anticipates that after randomization, but before the endpoint can be observed, up to 15% 
of the subjects will drop out from the study irrespective of study arm and success of treatment; thus , an 
adjustment for this drop -out rate is made and a sample size of 124 is required at the point of 
randomization.  
We s hall randomize an additional up to 36 subjects (30+15% dropout) in the age range 18 -21 to assess 
efficacy in this age range as well.  
12.5.  Interim Analysis  
Planning one interim analysis that permits an increase in the sample size as described below does not 
addi tionally inflate the type I error [38]–[41]. In addition, the final analysis is performed using the 
conventional test as appropriate for the statistical hypothesis.  
An interim analysis will be performed by [CONTACT_132629] 80% of the  required 
num ber of subjects aged [ADDRESS_149810] e size, stop for futility, stop for efficacy , or continue with an increased sample 
size. These decisions will be made based on the conditional power (CP), which is defined as the conditional 
probability that the result will exceed a critical value at the interim given the observed effect size.  
Note that the interim analysis will be conducted on the ITT, mITT , PP and mYITT analysis sets, and the 
study will be stopped due to futility only if the interim effects in all populations fall below the CP 
thresh old. 
12.5.1.  Procedure  
After all the relevant data will be entered into the database, and the database cleaned, a soft lock to the 
database will be performed. An independent un -blinded statistician (not the study statistician) will 
perform the assessments describe d below. A designated data monitoring team will recommend whether 
to stop the study once the interim results are available.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 72 of 92 
 
Neurolief Confidential  
  
  
At the interim analysis, the data of the evaluable subjects in the ITT, mITT , PP and mYITT  sets will be 
analyzed.  
12.5.2.  Blinding  
Only the unblinded statistician and members of the data monitoring committee (DMC)  will be exposed to 
the interim report. The members of the data monitoring team may also have access to the unmasked 
information of the interim analysis. Investigators and co mpany directors will only be informed of a 
decision to continue or to discontinue the trial, or to implement modifications in trial procedure. The un -
blinded statistician who is responsible for conducting the interim analyses should ensure that the 
unmaske d data is not available to any unauthorized person within or outside the company.  
12.5.3.  Decision Rules  
The study will either continue to the originally planned sample size if the result is “favorable”, stop for 
futility if the result is “unfavorable”, stop for s uccess if the result is “overwhelming” or an increase will 
be made to the sample size if the result is “promising”. These decisions will be made based on the 
conditional power (CP), defined as the conditional probability that the result will exceed a criti cal value 
at the interim given the observed effect size  𝛿1̂  = difference between mean change in HDRS17 scores 
for the active versus sham groups at the interim look.  
Notation:  
n1= sample size at interim analysis.  
n2= original sample size calculated based on assumed effect size.  
nmax = the hi ghest sample size the company is willing to use, nmax = [ADDRESS_149811] size of 0. 356. 
CPmin=is the calculated minimum CP based on the ratios nmax /n2, n1/n2 and the target study power 
(80%).  
The following are the decision rules for the interim analysis which will be performed upon accrual of ~80% 
of the sample size, 86 evaluable subjects:  
• If the result is “Unfavorable”, i.e. CP < CPmin = 29.14 % (int erim result is so disappointing that it is not 
worth increasing the sample size to retrieve conditional power), then stop the trial for futility.  
• If the result is “Promising”, i.e. 29.14 % ≤ CP < 80% the sample size is increased recover the targeted 
power o f 80%. The sample size used will be either the new calculated sample size based on the 
conditional power (as described in Sample size re calculation using conditional power Jonathan S. 
Denne Statist. Med. 2001; 20:2645 –2660) or the predetermined maximum sa mple size of 250 
subjects.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 73 of 92 
 
Neurolief Confidential  
  
  
• If the result is “Favorable”, i.e. CP ≥ 80% the interim results are sufficiently favorable, and the trial 
continues to the original sample size planned of 106 (before allowance for dropouts) without the need 
to adaptively increas e the sample size.  
• If the result is “overwhelming” i.e. primary endpoint at the interim analysis is statistically significant 
at a 0.[ZIP_CODE] level of significance, then stop the study for success. This was calculated based on an 
adaptive design with one inte rim analysis planned to either stop the study for futility or early success 
at the interim with a Lan -DeMets alpha spending approach using a Pocock type function, where at  the 
interim the study will be stopped for success if the null hypothesis is rejected  at an alpha level of 0. 
[ZIP_CODE].  
 
Note that the interim analysis will be conducted on all populations (ITT, mITT , PP and mYITT  analysis sets, 
see Section 12. 7), and the study will be stopped due to futility only if the interim effects in all populations 
fall below the threshold.   
The un -blinded statistician will also calculate the sample size required to test the null hypothesis to 
achieve 80% power at 4.108% level of significance given the current trend.  
 
12.5.4.  Controlling the Alpha Level for the Primary Endpoint  
The overall alpha level for this study is 5%. According to [ Müller 2001; Jonathan 2001 Broberg  2013  and 
Siu 2001 ], planning an interim analysis that permits an increase in the sample size as described above does 
not inflate the type I error.  
12.6.  Randomization  
Eligible subjects will be randomly allocated (with a 1:1 ratio) to one of the following 2 treatment groups 
based on a randomization scheme using the permuted block method stratified by [CONTACT_384]:  
• Active ( Relivion® DP) stimulation  
• Sham stimulatio n 
The randomization scheme will be prepared by [CONTACT_132534] (version 9.4.) random 
number procedure. The block size will be random, and all study personnel will be therefore blinded to the 
randomization block size.  
12.7.  Study Analysis Pop ulations  
12.7.1.  Intent -to-Treat (ITT) Population:  
The intent -to-treat (ITT) population will include all subjects aged [ADDRESS_149812] one active/sham treatment. 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 74 of 92 
 
Neurolief Confidential  
  
  
According to the ITT principle all subjects will be analyzed in the treatment group as assigned by 
[CONTACT_17628].  
12.7.2.  Modified Intent -to-Treat (mITT) Population:  
The modified intent -to-treat (mITT) population will include all subjects from the ITT set enrolled i n the 
study, who completed the minimal stimulation time required by [CONTACT_132630]. The mITT analysis set will be analyzed in the treatment group as treated.  
12.7.3.  Per-Protocol Population:  
All subjects from mITT s et that complete the 8-week treatment period (without withdrawal) and without 
any major protocol deviations.  
12.7.4.  Modified Younger Intent -to-Treat (mYITT) Population:  
The modified  younger  intent -to-treat (m YITT) population will include all subjects from the IT T set enrolled 
in the study including subjects aged [ADDRESS_149813] randomization exclusion criteria. The m YITT analysis set will be analyzed in the 
treatment group as treated.  
 
12.7.5.  Statistical Analysis of Analysis Sets  
Safety assessments will be performed on the ITT and mYITT analysis set.  
The mITT cohort will serve as the principal data analysis set for the primary and secondary statistical 
evaluation of the efficacy endpoints.  The p rimary, secondary and exploratory efficacy assessment will 
also be performed on the per protocol (PP) analysis set as a sensitivity analysis and to show consistency 
of study results.  The primary and secondary efficacy analyses will also be performed on the  mYITT 
analysis set.  
12.8.  Statistical Analysis  
12.8.1.  General Considerations  
Statistical analyses will be performed using SAS® v9.4 (SAS Institute, Cary NC, [LOCATION_003]). Statistical analyses 
and reporting will be performed in compliance with FDA Guidance E6 GCP, [ADDRESS_149814] deviation, minimum, median and maximum and 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 75 of 92 
 
Neurolief Confidential  
  
  
categorical variables by a cou nt and percentage. For comparison of means (continuous variables), the 
two-sample t -test or the Wilcoxon rank sum test will be used as appropriate. For comparison of 
proportions (categorical variables), the chi -squared test or Fisher’s exact test will be u sed as appropriate. 
If multiple measurements are taken in a single subject, statistics described below will be appropriately 
modified to accommodate the within subject correlation.  
Deviations from the planned analysis will be described, with proper justification, in the clinical study 
report.  
12.8.2.  Significance Level and Handling of Type I Error  
Type I Error:  
The overall significance level for this study is 5% using two -tailed tests, exce pt for treatment by [CONTACT_132631] a significance level of 10%  and the test for early efficacy at the interim 
look.  
Controlling the Overall Type I Error:  
The hierarchy approach will be adopted for the primary and secondary endpoint s to control type I error 
due to multiple endpoint testing. Thus, the primary endpoint will first be tested and only if p ≤.05, will the 
secondary endpoints be tested. For the three secondary performance endpoints, the Benjamini –Hochberg 
step -up method will  be used to adjust the p -values.  
12.8.3.  Demographic and Other Baseline Characteristics  
Demographic and baseline condition related characteristics will be tabulated and compared between the 
study groups by [CONTACT_89714]. Continuous variables will be summarized by a me an, standard deviation, 
minimum, median and maximum and categorical variables by a count and percentage. The statistical 
evaluation of baseline characteristics will include all available data from the ITT population . 
These data will include:  
• Demographic da ta  
• Medical history  
• Psychiatric history  
• Previous and Current Psychotropic Medication  
• Type, dose and frequency of concomitant medications  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149815] to follow -up, adverse event, poor compliance, did 
not administer any treatment (with reasons). A list of di scontinued patients, protocol deviations and 
subjects excluded from the efficacy analysis will be provided as well.  
Time to withdrawal will also be assessed and presented by [CONTACT_5263] -Meier curves and will be compared 
using the Log -Rank test if relevant.  
12.9.  Efficacy Analysis  
12.9.1.  Primary Efficacy Analyses  
The primary efficacy endpoint is the change from baseline to  [ADDRESS_149816] treatment initiation will be compared between the 
treatment groups using a repeated measures analysis of covariance (ANCOVA, SAS® MIXED procedure).  
The model will include the following fixed effects: treatment group, visit, treatment group by [CONTACT_132632] 17, and center entered  as covariates. Baseline HDRS [ADDRESS_149817] ical evaluation. 
Additionally, the center variable will be grouped by [CONTACT_132542] (OUS) and the analyses 
as for center will repeated on this new variable.  
The unstructured covariance matrix structure will be used. If the model does not  converge, then either 
the compound symmetry or autoregressive (whichever model has the lower AIC statistic) covariance 
matrix structure will be used instead .  At this time point (up to 8 weeks) we do not expect a high proportion 
of dropouts, as a placebo ef fect of the sham treatment is expected and was taken into consideration in 
the design of the study. Thus, any missing data at [ADDRESS_149818] treatment initiation will be estimated from the model (LS Means) 
interaction term for each group as well as the difference between the adjusted means and presented 
together with 95% confidence intervals.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 77 of 92 
 
Neurolief Confidential  
  
  
The null hypothesis will be r ejected in favor of the alternative hypothesis and the study deemed successful 
if the p -value is <0.05 and the mean change HDRS 17 in the active group is higher than that of the sham 
group . 
Cohen’s D will be calculated and presented as well as a measure of the clinical effect size of the change 
from baseline HDRS17 at week 8. An effect size can also be calculated using methods described in “Effect 
sizes for growth -modeling analysis for controlled clinical trial in the same metric as for classical analysis”, 
Psychol Methods . 2009 March; 14(1): 43 -53), where ES = difference between LSmeans / Pooled SD of 
baseline HDRS 17 score.  
Subset Analyses of Primary Endpoint:  
Significant or important variables, such as demographic or other baseline patient characteristics or 
concomitant medications (depending on use), will be entered as additional covariates in the primary 
efficacy endpoint ANCOVA model to evaluate their effect on the change from baseline HDRS 17 score.  
• Use of concomitant medications .  
• Blindi ng assessment  
• US vs. OUS sites  
 
The effect of potential  unblinding will be evaluated as a sensitivity analysis , where an additional binary 
variable identifying subjects unblinded versus those not un -blinded will be added to the ANCOVA model 
as a covariate . 
12.9.2.  Secondary Efficacy Analyses  
• Proportion of responder subjects - defined as the percent of subjects achieving at least 50% 
reduction from baseline in their HDRS17 total score, [ADDRESS_149819] Relivion® DP treatment initiation - 
will be summarized by a count and  percentage and compared between the groups with a chi -
squared test and a Fisher’s exact test . As an additional measure of effect size the NNT will be 
presented.  
• Proportion of subjects achieving remission - defined as the percent of subjects with HDRS17 
score≤[ADDRESS_149820]  Relivion® DP treatment initiation - will be summarized by a count and 
percentage and compared between the groups with a chi -squared test and a Fisher’s exact test . 
As an additional measure of effect size the NNT will be presented.  
• Mean Change in depressive symptoms, measured by [CONTACT_132633], from baseline to week -
[ADDRESS_149821] treatment initiation  - will be compared between the groups using a similar model as the 
primary endpoint . 
 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 78 of 92 
 
Neurolief Confidential  
  
  
12.9.3.  Exploratory Analyses  
• Mean Change in the severity and improvement scores - Clinical Global Impression scales (CGI -S 
and CGI -I) at [ADDRESS_149822] treatment initiation – will be compared between the groups using a 
similar model as the primary endpoint . 
• Mean Change from baseline in t otal score of the Quick Inventory of Depressive Symptomatology 
self-rated (QIDS -SR-16) score  at [ADDRESS_149823] treatment initiation – will be compared between the 
groups using a similar model as the primary endpoint . 
• Mean change in depressive symptoms, measur ed by [CONTACT_132536] [ADDRESS_149824] Relivion® DP treatment initiation  will be compared between the groups using a similar model 
as the primary endpoint . 
 
12.9.4.  Safety Analysis  
Descriptive statistics will be presented per study group for all safety parameters.  
The primary safety variable, the cumulative incidence (and 95% CI) of device related adverse events (AEs) 
throughout the study, will be presented in tabular format and will include incidence tables by [CONTACT_926].  
Adverse event rates will b e compared between the study groups with a Fisher’s exact test.  
Serious adverse events will be listed and discussed individually.  
The incidence of potentially clinically significant vital signs measurements will be presented at each 
relevant visit by [CONTACT_71930]. Descriptive statistics, as well as changes from baseline, will also be 
presented by [CONTACT_132634].  
Treatment tolerability will be compared between the study groups. The number and percent of subjects 
who fail to complete t he study and the number and percent of subjects who fail to complete the study 
because of Adverse Events will be presented as well.  
12.9.5.  Handling of Missing Data  
The study outcome will not be evaluated for patients who drop out prior to randomization. The prim ary 
endpoint will be analyzed using a repeated measures ANCOVA model which can handle data missing at 
random and we do not expect a high proportion of dropouts until the primary endpoint is measured. 
Therefore, for this evaluation no imputation of missing data is considered beyond the model estimates. 
Additionally, imputation of data such as by [CONTACT_132635] , therefore, for this 
evaluation no imputation of missing data is considered beyond the model estimates. Nevertheless, a 
sensit ivity analysis based upon last observed values (LOV) may be performed. The Last Observed Value 
(LOV) is defined as the last available post baseline visit data up to and including the last treatment visit or 
termination visit.  
For categorical variables (suc h as response and remission rates at week 8) the LOCF concept will be 
applied.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 79 of 92 
 
Neurolief Confidential  
  
  
Baseline characteristics of patients who drop out will be evaluated by [CONTACT_132636].  
12.9.6.  Pooling  
Subgroup analysis of the primary efficacy endpoint by [CONTACT_132637] , will be used to 
evaluate the poolability of the results. Treatment by [CONTACT_132638] a significance level of 10%. If the interaction is not signif icant, it will be removed from 
the model. If the interaction is found significant, it will also be removed from the model and the reason 
for this interaction will be further explored and rationalized. This evaluation may include demographic 
features, sympt oms at presentation, and clinical and treatment history, and center comparability in the 
features found to be associated with the primary efficacy variable.  
 In the case that poolability is questionable, the reasons for differential treatment effect, such as subject 
and clinical characteristics, will be investigated and reported.  
13. Ethics  
13.1.  Statement(s) of Compliance  
This study will be conducted in compliance with the protocol (after being approved  by [CONTACT_132639]/IRB 
and, if required, by [CONTACT_132640]), 21 CFR Parts 50, 54, 56 and 812 (as applicable for NSR device study), ISO 
[ZIP_CODE], and the ethical principles that have  their origin in the Declaration of Helsinki.  
The Informed Consent Form (ICF), patient's information material, and advertising material (if applicable) 
must be submitted and approved  by [CONTACT_1201]/EC (and RA when needed), and any request by [CONTACT_1201]/EC or 
RA w ill be followed. Written approval of the protocol, ICF, patient's information material, and any 
advertising material (if applicable) must be obtained from the EC/IRB and if applicable the corresponding 
RA prior to any patient enrollment.  
Adequate insurance  policy will be held valid for the entire study duration as well as for the discovery 
period required per local regulation.  
Information regarding the study and study data will be made available via publication on clinicaltrials.gov. 
Additionally, the resul ts of this study will be submitted for publication in an appropriate journal.  
14. Study Administration  
14.1.  Data monitoring committee  
An independent data monitoring committee (DMC) will be responsible for safeguarding the interests of 
trial participants by [CONTACT_132641] g the safety and efficacy of the interventions during the trial. The DMC will 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 80 of 92 
 
Neurolief Confidential  
  
  
provide recommendations to sponsor about stoppi[INVESTIGATOR_132505]/or the value of the information coll ected, or to protect the 
integrity of the study.  
The data reviewed by [CONTACT_132642] a summary of the following topi[INVESTIGATOR_1102]:  
• Safety monitoring: data related to the safety of the subjects, including any adverse events or side effects 
related to the trea tment  
• Efficacy monitoring: interim efficacy analysis and recommendations  
14.2.  Monitoring  
Monitoring will be conducted to ensure the protection and safety of human subjects, the quality and 
integrity of the clinical data, and compliance with the protocol.  
The site s will be monitored , in-person and/or remotely, by [CONTACT_132643]/or Contract Research 
Organizations (CROs)  who have received appropriate training , in accordance with the monitoring 
procedures set forth by [CONTACT_132530] .  The selected monitor s and qualification, extent of SDV, timing and 
frequency of monitoring visits, the essential documents to be reviewed, and other study -specific 
monitoring requireme nts will be addressed in the monitoring plan  that will be developed by [CONTACT_132644]/or the monitoring CRO.  Monitoring may be performed with in person visits or remotely, when 
applicable.   Quality documents will be followed for the conduct of all activiti es related to monitoring for 
this study.  
Site Qualification and Initiation Visits will be completed prior to enrollment of the first subject.  
14.2.1.  Initiation Visit  
The sponsor and a qualified monitor will conduct an initiation visit at the beginning of the study to ensure 
that the PI [INVESTIGATOR_132506]:  
• Have been trained on the use of the Relivion® DP. 
• Understand the requirements and/or contents of the protocol, CRF/ eCRF, the Relivion® DP User 
Manual, questionnaires , applicable regulations, and the Clinica l Trial Agreement (CTA).  
• Are familiar with the responsibilities of the PI.  
14.2.2.  Monitoring Visits  
In order to comply with the applicable regulations concerning the conduct of clinical studies, to assure the 
accuracy of the study database, and to assure the over all quality and consistency of the study, a qualified 
monitor will visit the site s during the course of the study in order to review the study records.  
The monitor will:  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 81 of 92 
 
Neurolief Confidential  
  
  
• Compare study data with any relevant source documents, such as patient’s medical recor ds, data 
tracings/printouts, etc.  
• Check the consent form for each patient.  
• Check the general study records, including device accountability.  
• Check the occurrence of possible adverse events.  
• Check compliance with the protocol, CTA, and applicable regulation s. 
All monitoring visits to the investigational center will be recorded using the Monitoring Visit Log. The log 
will be kept in the site regulatory binder and a copy will be collected and submitted to the Sponsor.  
The Study Investigator and the investigating site will permit authorized clinical research personnel and 
clinical monitors from Neurolief and/or designee(s) employed by [CONTACT_132645]/ eCRFs, IRB/EC decisions, and clinical site records, a nd facilities relevant to this study at regular 
intervals throughout the study per the monitoring plan. Additionally, subject charts and clinical records 
will be requested and reviewed so that protocol adherence and source documentation can be verified. In  
instances where data protection regulations prohibit the direct examination of hospi[INVESTIGATOR_132507](s), the Investigator will cooperate in a system of source data verification with 
the Sponsor.  
To ensure the rights, safety, a nd welfare of study subjects are being maintained, the monitor will review 
training records to ensure all study staff are adequately trained on the study protocol and use of the study 
devices. If the monitor discovers that an Investigator is not complying with the signed Investigator 
Agreement, the investigational plan, applicable laws, or any conditions of approval imposed by [CONTACT_54455]/EC, the monitor will report to the Sponsor and take such steps necessary to promptly secure 
compliance. If complia nce cannot be secured, device shipments to the Investigator may be discontinued 
and the Investigator’s participation in the investigation terminated. The monitor shall also require such 
an Investigator to dispose of or return the device, unless this action  would jeopardize the rights, safety, 
or welfare of a subject . 
14.2.3.  Data Queries  
During monitoring visits, the Monitor will perform a source verification of required data points that 
comprise the CRF/ eCRF for each subject.  Discrepancies will be queried by [CONTACT_132646] [INVESTIGATOR_2993] a timely manner, and as requested by [CONTACT_132530] .  Manual and/or 
automatic queries will be created in the CRF/ EDC system and will be issued to the site for appropriate 
response.  The sit e staff will be responsible for responding to all queries in the database. In the event of 
data discrepancies, investigational sites  will be asked to resolve queries electronically in the EDC system; 
otherwise, irresolvable data -related issues will be rout ed to the Sponsor for review and final disposition.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 82 of 92 
 
Neurolief Confidential  
  
  
14.2.4.  Close -Out Visit  
Upon completion of the clinical study, the sponsor or designee will notify the site of closeout and a study 
closeout visit will be performed.  All study devices and any unused study materi als will be collected and 
returned to the sponsor, if not done earlier.  The monitor will ensure that the investigator’s regulatory 
files are up -to-date and complete, and that any outstanding issues from previous visits have been 
resolved.  Other issues wh ich will be reviewed at this visit include discussing retention of study files, 
possibility of site audits, publication policy, and notifying the EC/IRB of study closure.  
14.3.  Audits and Inspections  
The sites may be subject to quality assurance audits by [CONTACT_132647], as 
well as inspections by [CONTACT_132648].  
In the event that an audit is initiated by [CONTACT_132649] a designee, the investigator shall allow access to the 
original medical records and provide all requested information. In the event that an inspection is initiated 
by a regulatory authority, the investigator shall immediately notify Neurolief  of the im pending inspection 
and allow the regulatory body access to the medical records and other information as required by 
[CONTACT_774] . 
14.4.  Direct Access to Source Data/Documents  
Source data is all information, original records of clinical findin gs, observations, or other activities in a 
clinical study necessary for the reconstruction and evaluation of the study.  Source data are contained in 
source documents. Examples of these original documents and data records include, but are not limited 
to: h ospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, patients’ evaluation 
checklists, patient’s diary, recording media such as DVD and video tapes, x -rays, patient files,  subject PRO 
(electronic or hard copy)  and records kept at the la boratories, and at other departments involved in the 
clinical trial.  
Source documents will be used:  
• For verification of the data documented in patient CRF/eCRFs during monitoring visits, audits and 
inspections.  
• For the adjudication of adverse events.  
Duri ng monitoring visits, audits, and inspections, the PI [INVESTIGATOR_132508], 
patient CRF/eCRFs, and patient medical records to Neurolief  staff and other sponsor designees, as well as 
representatives of regulatory agencies. It is i mportant that the investigators and the relevant site 
personnel are available during monitoring visits and possible audits and inspections and that sufficient 
time is devoted to the process.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 83 of 92 
 
Neurolief Confidential  
  
  
14.5.  Data Management  
All data will be collected using a paper CRF or Remote Electronic Data Collection ( RDC/ EDC) system. The 
clinical sites will use hard copy or electronic case report forms (eCRFs) to document the information 
required by [CONTACT_4690].  
The EDC allows for the secure collection, transmission, validation , monitoring and real -time 
administration of study data gathered at investigative sites. The system allows password -restricted access 
to clinical trial information based on individuals' roles and responsibilities.  The EDC are compliant with 21 
CFR Part 11  and FDA’s “ Guidance: Computerized Systems Used in Clinical Trials. ” 
Data reported on the CRF/ eCRF should be driven from source documents ( Section 14.3 ) and be consistent 
with these source documents. Editing of data is done under full audit trail.  Paper C RF worksheets may be 
provided to the investigational site to assist with data collection for the required fields.  
Required data will be recorded on  CRF/eCRFs by [CONTACT_132650]. The Investigator wil l ensure that all eCRFs are completed promptly, completely, and 
accurately. Information on case report forms must conform to the information in the source documents.  
The Sponsor will oversee and/or perform all data management functions. Data management fun ctions 
include database development, system maintenance, data queries, and report generation.  
Investigators must ensure that clinical records clearly indicate that the subject has been enrolled in a 
clinical investigation. Regulations require that Investi gators maintain information in the study subject’s 
medical records to corroborate data collected on the CRF/ eCRF. In order to comply with these regulatory 
requirements, the study site will manage the following information, and retain/manage it as required to 
make it available to monitors, auditors and/or regulatory bodies. Complete hospi[INVESTIGATOR_132509], labs and assessments as noted 
in Study schedule and Site Collection Dat a. 
14.5.1.  Direct Data Entry  
For several CRF fields Source Data Verification (SDV) may not be possible as entries may not be found in 
source documents.  Therefore, it is allowed to use the CRF/ eCRF for direct data entry, but only for pre -
defined fields.   
14.5.2.  Data Quality Assurance  
To ensure the quality of clinical data across all subjects, a clinical data management review will be 
performed on subject data submitted in the CRF/ eCRF.  During this review, subject data will be checked 
for consistency, omissions, and a ny apparent discrepancies.  In addition, the data will be reviewed for 
adherence to the protocol and relevant regulations.  To resolve any questions arising from the clinical 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 84 of 92 
 
Neurolief Confidential  
  
  
data management review process, data queries and/or site notifications will be is sued.  Discrepancy 
resolution will be documented within the database audit trail.  
The development of the primary database for the study will be managed by [CONTACT_132530] . Neurolief  will also 
be responsible for the quality control of the database and confirming the overall integrity of the data.  
Corresponding queries will be issued to site coordinator. Effort will be made to resolve such queries as 
close as possible to real time.  
14.5.3.  Electronic Signatures  
The PI [INVESTIGATOR_132510]/ electronically sign each individual CRF/ eCRF after the data has been cleaned, 
monitored and reviewed.  The hand write/ electronic signature [CONTACT_132659], the data queries, and the site notification s, and agrees with the content.  
Any changes made to the data after PI [INVESTIGATOR_132511], and the PI [INVESTIGATOR_132512] -sign the data after reviewing the change(s).  
14.6.  Confidentiality  
Subject confidentiality will be maintained throughout the clinical study in a way that ensures the 
information can always be tracked back to the source data.  For this purpose, each subject will be 
identified by a dedicated  study code .  Records, including investig ator site file, will remain on site in secure 
areas.  Possible review and photocopying of the subject’s records by [CONTACT_132651].  Additionally, Neurolief and its representatives may review and photocopy the 
subject’s r ecords.  In such cases and in the event subject’s data are used for educational, presentation, 
and/or publication purposes, subject identity will be masked to protect the subject’s confidentiality.  
The subjects will be informed in writing that representati ves of the Sponsor, IRB or Regulatory Authorities 
may inspect their medical records to verify the information collected, and that all personal information 
made available for inspection will be handled in strictest confidence and in accordance with local da ta 
protection laws.  
Subjects will also be informed that information regarding the study that does not include subject 
identifiers will be posted on clinicaltrials.gov  and the mytrails.com Israeli  MOH website .  
If the results of the study are published, th e subject’s identity will remain confidential. The Investigator 
will maintain a list to enable subjects’ records to be identified.  
Regulatory agencies and Neurolief are required to maintain the privacy of all records they review in 
connection with this study.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149825] of the risks involved in conducting this study according to this protocol.  The 
insurance policy will be fil ed in the study file and can be made available to the investigator and to the 
EC/IRB upon request.  
14.8.  CIP Amendments  
CIP amendments, except where necessary to eliminate an immediate hazard to patients, will be issued by 
[CONTACT_132530] . Agreement from the investiga tor must be obtained for all protocol amendments and 
amendments to the informed consent document. The  IRB/ EC must be informed of all amendments and 
give written approval, which must be provided to Neurolief . Notification to the relevant Competent 
Authoriti es will take place as required locally.  IRB/EC approval, site training and a new acknowledgement 
form will be signed and returned before any new procedures take place . 
14.9.  Record Retention  
Essential study documents will be maintained both on -site (within the i nvestigator site file) and in -house 
(both study and site records).  
The sponsor and PI [INVESTIGATOR_132513](s).  Documents should not be destroyed without the permission of the sponsor.  In the event 
of the PI [INVESTIGATOR_132514], it is the PI’s responsibility to notify the sponsor in writing and to designate 
which study material will be transferred from / maintained at the clinical site.  
Subject files and other source data must be kept  for a period of not less than 2 years after the latter of 
the following two dates: the date on which this investigation is terminated or completed, or the date that 
the records are no longer required for purposes of supporting a premarket application. Rec ords may need 
to be maintained by [CONTACT_13177] a longer duration if national regulations require or if agreed to in 
writing with Neurolief . 
14.10.  Publication and Use of Information  
It is the policy of Neurolief  to publish the results of clinical studies.  Specifics of the arrangements of study 
publication will be addressed in the clinical trial agreement.  
Information regarding the study and study data will be made available via publication on clinicaltrials.gov  
and the Israeli MOH web site.  
Investigators m ust submit a copy of all manuscripts and/or abstracts to Neurolief for review and comment 
30 days prior to planned submission. Neurolief acknowledges that its right to review and comment shall 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 86 of 92 
 
Neurolief Confidential  
  
  
relate solely to the proprietary, licensing, and/or confidentia l rights Neurolief may have in such proposed 
publication, rather than whether such results and/or opi[INVESTIGATOR_132515] .  
The publication of sub -studies, post -hoc analyses, regional results, or single -center experiences based on 
multicenter clinical studies should not precede that of the primary multicenter publication, and should 
cite the primary publication whenever possible, as required by [CONTACT_132652].  
14.11.  Funding  
The study is funded by [CONTACT_132653]., Israel.  
14.12.  Suspension or Early Termination  
The final sample size will be determined following completion of the interim analysis and t he study will 
be considered completed when the last patient completes the final study visit.  Premature terminatio n of 
this clinical study may occur for statistical reasons due to insufficient effectiveness of the investigational 
device (see Section 12.5). Additionally, early termination may occur because of a regulatory authority 
decision, change in opi[INVESTIGATOR_1100]/EC, or at the discretion of sponsor or the PI.  
Neurolief  will monitor the progression of the clinical investigation.  If warranted, the clinical investigation 
may be suspended or discontinued early if there is an observation of serious adverse reactions presenting 
an unreasonable risk to the clinical investigation population.  
Neurolief may terminate investigator and site  participation in the clinical investigation if there is evidence 
of failure to maintain adequate clinical standards, failure to comply with the clinical investigational plan, 
fraud or any other forms of misconduct.  
Last, Neurolief reserves the right to d iscontinue the clinical trial/investigation at any stage, with suitable 
written notice to the investigator. Possible reason(s) include:  
• Per medical advisor’s recommendation (such as higher frequency of anticipated adverse device 
effects, endpoint is met, or futility).  
• Further product development is cancelled.  
In the event of clinical investigation premature termination or suspension, Neurolief will send a report 
outlining the circumstances to the corresponding ethics committee, regulatory body and all inv estigators . 
The appropriate ethics committees will be notified of discontinuation of the study for any reason no later 
than 5 working days after the Sponsor makes this determination .  A suspended or terminated clinical 
investigation may not be re -initiated  without approval of the corresponding EC /IRB  and relevant 
competent authority  (as applicable) .  In the event of clinical investigation premature termination or 
suspension, enrolled subjects will be followed up as per the institution’s standard of care.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June [ADDRESS_149826] 
follow -up shall be reported to Neurolief on the appropriate eCRF.  
Suspension or termination of a site may include but is not limited to:  
• Ethics Board approval expi[INVESTIGATOR_1516]  
• Consistent non -compliance to the protocol (e.g. failure to follow subjects, etc.)  
• Lack of enrollment  
• Non -compliance to regulations and the terms of the Agreement with Neurolief  
• Ethics Board suspension of the site  
If the site terminates or suspends participation witho ut prior agreement of Neurolief : 
• The site must promptly inform Neurolief  and provide a detailed written explanation of the termination 
or suspension .  
• The site must promptly inform the institution (where required per regulatory requirements)  
• The site must  promptly inform the Ethics Board, if applicable  
If the Ethics Board terminates or suspends its approval:  
• The site must promptly inform Neurolief  and provide a detailed written explanation of the termination 
or suspension within 5 working days.  
• Patient enrollment must stop until the Ethics Board suspension is lifted .  
• Subjects already enrolled should continue to be followed in accordance with the Ethics .  
• Board policy or its determination that an overriding safety concern or ethical issue is involved .  
• The site must inform his/her institution (where required per local requirements)  
• The site must promptly inform the patients, if applicable  
 
The PI [INVESTIGATOR_132516]/ EC in writing of the study’s completion or early termination and provide a 
copy of the notification to Neurolief . 
 
15. References  
[1] M. Shadrina, E. A. Bo ndarenko, and P. A. Slominsky, “Genetics factors in major depression 
disease,” Frontiers in psychiatry , vol. 9, p. 334, 2018.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 88 of 92 
 
Neurolief Confidential  
  
  
[2] J. Bueno -Notivol, P. Gracia -García, B. Olaya, I. Lasheras, R. López -Antón, and J. Santabárbara, 
“Prevalence of depression duri ng the COVID -19 outbreak: a meta -analysis of community -based 
studies,” International Journal of Clinical and Health Psychology , p. 100196, 2020.  
[3] M. B. Generoso et al. , “Effect of a 10 -day transcutaneous trigeminal nerve stimulation (TNS) 
protocol for d epression amelioration: A randomized, double blind, and sham -controlled phase II 
clinical trial,” Epi[INVESTIGATOR_002] & Behavior , vol. 95, pp. 39 –42, 2019.  
[4] M. Marcus, M. T. Yasamy, M. van van Ommeren, D. Chisholm, and S. Saxena, “Depression: A 
Global Public Healt h Concern: (517532013 -004).” American Psychological Association, 2012, doi: 
10.1037/e517532013 -004.  
[5] S. Rathod et al. , “The current status of culturally adapted mental health interventions: a practice -
focused review of meta -analyses,” Neuropsychiatr Dis  Treat , vol. 14, pp. 165 –178, Jan. 2018, doi: 
10.2147/NDT.S138430.  
[6] K. Weihs and J. M. Wert, “A Primary Care Focus on the Treatment of Patients With Major 
Depressive Disorder,” Am J Med Sci , vol. 342, no. 4, pp. 324 –330, Oct. 2011, doi: 
10.1097/MAJ.0b013e318210ff56.  
[7] A. M. Chekroud et al. , “Cross -trial prediction of treatment outcome in depression: a machine 
learning approach,” The Lancet Psychiatry , vol. 3, no. 3, pp. 243 –250, 2016.  
[8] I. A. Cook, R. Espi[INVESTIGATOR_103881], and A. F. Leuchter, “Ne uromodulation for Depression: Invasive and 
Noninvasive (Deep Brain Stimulation, Transcranial Magnetic Stimulation, Trigeminal Nerve 
Stimulation),” Neurosurgery Clinics , vol. 25, no. 1, pp. 103 –116, Jan. 2014, doi: 
10.1016/j.nec.2013.10.002.  
[9] P. Shiozawa , M. E. da Silva, T. C. de Carvalho, Q. Cordeiro, A. R. Brunoni, and F. Fregni, 
“Transcutaneous vagus and trigeminal nerve stimulation for neuropsychiatric disorders: a 
systematic review,” Arquivos de neuro -psiquiatria , vol. 72, no. 7, pp. 542 –547, 2014.  
[10] C. M. DeGiorgio et al. , “Randomized controlled trial of trigeminal nerve stimulation for drug -
resistant epi[INVESTIGATOR_002],” Neurology , vol. 80, no. 9, pp. 786 –791, Feb. 2013, doi: 
10.1212/WNL.0b013e318285c11a.  
[11] L. M. Schrader, I. A. Cook, P. R. Miller, E. R . Maremont, and C. M. DeGiorgio, “Trigeminal nerve 
stimulation in major depressive disorder: First proof of concept in an open pi[INVESTIGATOR_4251],” Epi[INVESTIGATOR_002] & 
Behavior , vol. 22, no. 3, pp. 475 –478, Nov. 2011, doi: 10.1016/j.yebeh.2011.06.026.  
[12] P. Shiozawa, M.  E. da Silva, G. T. M. Netto, I. Taiar, and Q. Cordeiro, “Effect of a 10 -day trigeminal 
nerve stimulation (TNS) protocol for treating major depressive disorder: A phase II, sham -
controlled, randomized clinical trial,” Epi[INVESTIGATOR_002] & Behavior , vol. 44, pp. 23 –26, Mar. 2015, doi: 
10.1016/j.yebeh.2014.12.024.  
[13] A. P. Trevizol et al. , “Trigeminal Nerve Stimulation (TNS) for Major Depressive Disorder in the 
Elderly: An Open Label Proof -of-Concept Trial,” Brain Stimulation , vol. 9, no. 1, pp. 146 –147, Jan. 
2016, d oi: 10.1016/j.brs.2015.10.002.  
[14] G. Aston -Jones et al. , “Afferent regulation of locus coeruleus neurons: anatomy, physiology and 
pharmacology,” in Progress in brain research , vol. 88, Elsevier, 1991, pp. 47 –75. 
[15] D. de Ridder, “BRAIN AND NERVE STIMUL ATION FOR MOOD ENHANCEMENT,” p. 14.  
[16] T. Bartsch, “Migraine and the neck: new insights from basic data,” Current pain and headache 
reports , vol. 9, no. 3, pp. 191 –196, 2005.  
[17] S. D. Silberstein et al. , “Safety and efficacy of peripheral nerve stimula tion of the occipi[INVESTIGATOR_132517]: Results from a randomized, multicenter, double -blinded, 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 89 of 92 
 
Neurolief Confidential  
  
  
controlled study,” Cephalalgia , vol. 32, no. 16, pp. 1165 –1179, Dec. 2012, doi: 
10.1177/0333102412462642.  
[18] G. Serra and F. Marchioretto, “Occipi[INVESTIGATOR_132518]: a randomized 
trial,” Pain physician , vol. 15, no. 3, pp. 245 –253, 2012.  
[19] M. Thimineur and D. De Ridder, “C2 Area Neurostimulation: A Surgical Treatment for 
Fibromyalgia,” Pain Medicine , vol. 8, no. 8, pp. 639 –646, Nov. 2007, doi: 10.1111/j.1526 -
4637.2007.[ZIP_CODE].x.  
[20] J. R. Saper et al. , “Occipi[INVESTIGATOR_132519]: ONSTIM feasibility study,” Cephalalgia , vol. 31, no. 3, pp. 271 –285, Feb. 2011, doi: 
10.1177/0333102410381142.  
[21] T. J. Schwedt, “Occipi[INVESTIGATOR_132518] --interpreting the ONSTIM 
feasibility trial,” Cephalalgia , vol. 31, no. 3, pp. 262 –263, Feb. 2011, doi: 
10.1177/0333102410383 591.  
[22] H. E. Ahmed, P. F. White, W. F. Craig, M. A. Hamza, E. A. Ghoname, and N. M. Gajraj, “Use of 
Percutaneous Electrical Nerve Stimulation (PENS) in the Short term Management of Headache,” 
Headache: The Journal of Head and Face Pain , vol. 40, no. 4, pp. 311 –315, 2000.  
[23] R. S. Tubbs, E. G. Salter, J. C. Wellons, J. P. Blount, and W. J. Oakes, “Landmarks for the 
identification of the cutaneous nerves of the occiput and nuchal regions,” Clinical Anatomy , vol. 
20, no. 3, pp. 235 –238, 2007.  
[24] O. Muel ler et al. , “Stimulation of the greater occipi[INVESTIGATOR_17719]: anatomical considerations and clinical 
implications,” Pain physician , vol. 16, no. May -June (3), pp. E181 –E189, 2013.  
[25] M. Philippe Magown, R. Garcia, I. Beauprie, and I. M. Mendez, “Occipi[INVESTIGATOR_132520]: an open surgical technique,” Clinical neurosurgery , vol. 56, p. 119, 
2009.  
[26] K. L. Reed, “Peripheral Neuromodulation and Headaches: History, Clinical Approach, and 
Considerations on Underlying Mechanis ms,” Current Pain and Headache Reports , vol. 17, no. 1, 
Jan. 2013, doi: 10.1007/s11916 -012-0305 -8. 
[27] R. Roy et al. , “Factors Associated with Migraine in the General Population of Spain: Results from 
the European Health Survey 2014,” Pain Med , vol. 20, n o. 3, pp. 555 –563, Mar. 2019, doi: 
10.1093/pm/pny093.  
[28] V. Yilmaz, B. Aras, F. A. Erturk, F. A. Cakcı, and E. Umay, “Migraine in patients with fibromyalgia and 
outcomes of greater occipi[INVESTIGATOR_132521],” Clinical Neurology and Neurosurgery , vol. 181,  pp. 
54–57, Jun. 2019, doi: 10.1016/j.clineuro.2019.04.004.  
[29] K. Reed, S. Black, C. Banta, and K. Will, “Combined occipi[INVESTIGATOR_132522]: Initial experience,” Cephalalgia , vol. 30, no.  3, pp. 
260–271, Mar. 2010, doi: 10.1111/j.1468 -2982.2009.[ZIP_CODE].x.  
[30] K. L. Reed et al. , “Combined occipi[INVESTIGATOR_132523]: an extended case series,” Cephalalgia , vol. 31, no. Suppl 1, p. 98, 2011.  
[31] S. Hann and A. Sharan, “Dual occipi[INVESTIGATOR_132524]: a 
single -center experience, review of literature, and surgical considerations,” FOC, vol. 35, no. 3, p. 
E9, Sep. 2013, doi: 10.3171/2013.6.FOCUS13233.  
[32] J. F. Jiang, A. N. Diaz, M. Campbell, N. M. Boulis, and O. P. Keifer, “Supraorbital Occipi[INVESTIGATOR_132525]: A Case 
Series,” World Neurosurgery , vol. 124, pp. e417 –e423, Apr. 2019, doi: 
10.1016/j.wneu.2018.12.108.  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 90 of 92 
 
Neurolief Confidential  
  
  
[33] S. Gu, W. Wang, F. Wang, and J. H. Huang, “Neuromodulator and emotion biomarker for stress 
induced mental disorders,” Neural plasticity , vol. 2016, 2016.  
[34] F. Willoch, U. Gamringer, R. Medele, U. Steude, and T. R. Tölle, “A nalgesia by [CONTACT_132654]: a PET activation study:,” Pain , vol. 
103, no. 1, pp. 119 –130, May 2003, doi: 10.1016/s0304 -3959(02)[ZIP_CODE] -2. 
[35] M. S. Matharu, “Central neuromodulation in chr onic migraine patients with suboccipi[INVESTIGATOR_132526]: a PET study,” Brain , vol. 127, no. 1, pp. 220 –230, Jan. 2004, doi: 
10.1093/brain/awh022.  
[36] “Use of Electronic Informed Consent Questions and Answers,” p. 16, 2016.  
[37] H.-H. Müller and H. Schäfer, “ Adaptive group sequential designs for clinical trials: combining the 
advantages of adaptive and of classical group sequential approaches,” Biometrics , vol. 57, no. 3, 
pp. 886 –891, 2001.  
[38] J. S. Denne, “Sample size recalculation using conditional power,”  Statistics in medicine , vol. 20, no. 
17–18, pp. 2645 –2660, 2001.  
[39] P. Broberg, “Sample size re -assessment leading to a raised sample size does not inflate type I error 
rate under mild conditions,” BMC medical research methodology , vol. 13, no. 1, pp. 1 –7, 2013.  
[40] C. O. Siu and K. K. Gordon Lan, “Flexible interim analysis method for sample size re -estimation and 
early stoppi[INVESTIGATOR_007]: a conditional power approach,” in Annual Meeting of the American Statistical 
Association: August , 2001, pp. 5 –9. 
 
 
 
 
 
 
 
 
 
 
 
 
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 91 of 92 
 
Neurolief Confidential  
  
  
16. Version History  
 
Version  Summary of Changes  Author(s)/Title  
1.0 new issue  Keren Ron  
Clinical study manager, 
Neurolief  
2.0  Updated inclusion/exclusion criteria, secondary  and 
exploratory endpoints , adding an OLE stage  and study flow . 
added the central trainer role and the sites  raters training .  Yaron Gruper  
Clinical study manager, 
Neurolief   
3.0 • updated inclusion/exclusion criteria,   
• updated assessment of safety (section 9.9)    
• the length of the DB and OL treatments stages were 
prolonged to 8 weeks each. Updated  “Expected 
treatment time for total DB phase” as a result of DB 
period time extension  
• Re-evaluation of the assigned treatment regimens 
according to the subjects’ MDD asses sment was 
added to visit 5 procedures   
• Up to 36 additional subjects ages 18 -21 are added to 
the study overall sample size . Analyses sets and 
statistical analysis sections update accordingly .  
• Updated sections 9.9, 9.12 & 10.1 to withdraw 
subjects with a “y es” answer to c -SSRS Q4 and Q5  
• Device and dedicated app SW versions updated  to 
support  users with  IOS12 and above.   
• Updated  maximum sample  size upon IA results to 250 
(instead of 200) and the respective IA decision  rules .  
 Yaron Gruper  
Clinical study manager, 
Neurolief  
 
 
 
 
 
 
 
 
 
 
 
 
  
 MOOD :  
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-201  
Rev: REV. 3 / 09June 2021 
Pg. 92 of 92 
 
Neurolief Confidential  
  
  
17. Appendi xes  
 